Medical device delivery system including a resistance member

Information

  • Patent Grant
  • 11241312
  • Patent Number
    11,241,312
  • Date Filed
    Tuesday, December 10, 2019
    6 years ago
  • Date Issued
    Tuesday, February 8, 2022
    3 years ago
Abstract
Example medical device delivery systems are disclosed. An example delivery system for an implantable medical device includes an outer shaft having a distal end region, a proximal end region and a lumen extending therebetween. The delivery system also includes a handle coupled to the proximal end region of the outer shaft, wherein the handle includes a first actuator, a carriage and a housing. The delivery system also includes a selector coupled to the handle and a resistance member disposed along a portion of the selector. Further, the selector is configured to shift between a first configuration and a deployment configuration. Additionally, the carriage is free from the resistance member in the first configuration and the resistance member contacts the carriage in the deployment configuration.
Description
TECHNICAL FIELD

The present disclosure pertains to medical devices, and methods for manufacturing medical devices. More particularly, the present disclosure pertains to medical device delivery systems including a translating engagement member.


BACKGROUND

A wide variety of intracorporeal medical devices have been developed for medical use, for example, intravascular use. Some of these devices include guidewires, catheters, and the like. These devices are manufactured by any one of a variety of different manufacturing methods and may be used according to any one of a variety of methods. Of the known medical devices and methods, each has certain advantages and disadvantages. There is an ongoing need to provide alternative medical devices as well as alternative methods for manufacturing and using medical devices.


BRIEF SUMMARY

This disclosure provides design, material, manufacturing method, and use alternatives for medical devices. An example delivery system for an implantable medical device includes an outer shaft having a distal end region, a proximal end region and a lumen extending therebetween. The delivery system also includes a handle coupled to the proximal end region of the outer shaft, wherein the handle includes a first actuator, a carriage and a housing. The delivery system also includes a selector which may be in the form of a cap coupled to the handle and a resistance member disposed along a portion of the selector. Further, the selector is configured to shift between a first configuration and deployment configuration. Additionally, the carriage is free from the resistance member in the first configuration and the resistance member contacts the carriage in the deployment configuration.


Alternatively or additionally to any of the embodiments above, wherein the resistance member contacts an inner surface along a distal end region of the housing in the first configuration.


Alternatively or additionally to any of the embodiments above, wherein the resistance member contacts an inner surface along a distal end region of the carriage in the deployment configuration.


Alternatively or additionally to any of the embodiments above, wherein the carriage is configured to rotate, and wherein the resistance member is configured to increase a rotational force required to rotate the carriage in the deployment configuration.


Alternatively or additionally to any of the embodiments above, wherein the cap includes a circumferential groove positioned along a proximal end region thereof, wherein at least a portion of the resistance member is positioned along the groove.


Alternatively or additionally to any of the embodiments above, further comprising an implant loading device positioned adjacent the distal end region of the outer shaft.


Alternatively or additionally to any of the embodiments above, wherein the cap includes an inner surface, an outer surface and a wall extending therebetween, and wherein the cap includes an aperture extending through a wall of the cap.


Alternatively or additionally to any of the embodiments above, wherein the aperture includes a length, and wherein the length of the aperture corresponds to a distance along which the cap shifts between the first configuration and the deployment configuration.


Alternatively or additionally to any of the embodiments above, wherein the aperture is aligned along a longitudinal axis of the cap.


Alternatively or additionally to any of the embodiments above, wherein the aperture is offset from a longitudinal axis of the cap.


Alternatively or additionally to any of the embodiments above, wherein rotating the cap shifts it between the first configuration and the deployment configuration.


Alternatively or additionally to any of the embodiments above, wherein the cap includes a circumferential lip extending circumferentially along a distal end region thereof.


Alternatively or additionally to any of the embodiments above, wherein the lip extends radially away from an outer surface of the cap.


Alternatively or additionally to any of the embodiments above, wherein the resistance member is configured to exert a radially outward force on an inner surface of the carriage in the deployment configuration.


Another example delivery system for an implantable medical device includes:


an outer shaft having a distal end region, a proximal end region and a lumen extending therebetween;


a handle coupled to the proximal end region of the outer shaft, wherein the handle includes a first actuator, a carriage and a housing;


a cap coupled to the handle; and


a resistance member disposed along a portion of the cap;


wherein the cap is configured to shift between a first configuration and a deployment configuration, and wherein the carriage is free from the resistance member in the first configuration and wherein the resistance member exerts a radially outward force upon the carriage in the deployment configuration.


Alternatively or additionally to any of the embodiments above, wherein the resistance member contacts an inner surface along a distal end region of the housing in the first configuration.


Alternatively or additionally to any of the embodiments above, wherein the resistance member contacts an inner surface along a distal end region of the carriage in the deployment configuration.


Alternatively or additionally to any of the embodiments above, wherein the carriage is configured to rotate, and wherein the resistance member is configured to increase a rotational force required to rotate the carriage in the deployment configuration.


An example method of manufacturing an implantable medical device includes:

    • engaging the implantable medical device with a medical device delivery system in a pre-deployment configuration, the medical device delivery system including: an outer shaft having a distal end region, a proximal end region and a lumen extending therebetween;
    • a handle coupled to the proximal end region of the outer shaft, wherein the handle includes a first actuator, a carriage and a housing;
    • a cap coupled to the handle; and
    • a resistance member disposed along a portion of the cap;
    • converting the medical device delivery system from a pre-deployment configuration to a deployment configuration, wherein converting the medical device delivery system includes shifting the cap from a first position to a second position, wherein the carriage is free from the resistance member when the cap is in the first position and wherein the resistance member contacts the carriage when the cap is in the second position.


Alternatively or additionally to any of the embodiments above, wherein the implantable medical device includes an implantable heart valve.


The above summary of some embodiments is not intended to describe each disclosed embodiment or every implementation of the present disclosure. The Figures, and Detailed Description, which follow, more particularly exemplify these embodiments.





BRIEF DESCRIPTION OF THE DRAWINGS

The disclosure may be more completely understood in consideration of the following detailed description in connection with the accompanying drawings, in which:



FIG. 1 illustrates an example medical device delivery system;



FIG. 2 illustrates an example step in the deployment of the example medical device shown in FIG. 1;



FIG. 3 illustrates another example step in the deployment of the example medical device shown in FIG. 1;



FIG. 4 illustrates a portion of the medical device system shown in FIGS. 1-3;



FIG. 5 is a cross-sectional view of an example handle of the medical device system shown in FIG. 1;



FIG. 6 is a perspective view of an example component of the medical device delivery system shown in FIG. 1;



FIG. 7 is a cross-sectional view of the example component of the medical device system shown in FIG. 5;



FIG. 8 is a cross-sectional view of a portion of the example handle shown in FIG. 1;



FIG. 9 is a cross-sectional view of a portion of the example handle shown in FIG. 1;



FIG. 10 is a perspective view of another example component of the medical device delivery system shown in FIG. 1;



FIG. 11 is a perspective view of an example stent loading device;



FIG. 12 is an exploded view of the example stent loading device shown in FIG. 11;



FIG. 13 is a cross-sectional view of the example stent loading device shown in FIG. 11.





While the disclosure is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the disclosure to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.


DETAILED DESCRIPTION

For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.


All numeric values are herein assumed to be modified by the term “about”, whether or not explicitly indicated. The term “about” generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In many instances, the terms “about” may include numbers that are rounded to the nearest significant figure.


The recitation of numerical ranges by endpoints includes all numbers within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).


As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.


It is noted that references in the specification to “an embodiment”, “some embodiments”, “other embodiments”, etc., indicate that the embodiment described may include one or more particular features, structures, and/or characteristics. However, such recitations do not necessarily mean that all embodiments include the particular features, structures, and/or characteristics. Additionally, when particular features, structures, and/or characteristics are described in connection with one embodiment, it should be understood that such features, structures, and/or characteristics may also be used connection with other embodiments whether or not explicitly described unless clearly stated to the contrary.


The following detailed description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention.


Diseases and/or medical conditions that impact the cardiovascular system are prevalent throughout the world. Traditionally, treatment of the cardiovascular system was often conducted by directly accessing the impacted part of the system. For example, treatment of a blockage in one or more of the coronary arteries was traditionally treated using coronary artery bypass surgery. As can be readily appreciated, such therapies are rather invasive to the patient and require significant recovery times and/or treatments. More recently, less invasive therapies have been developed, for example, where a blocked coronary artery could be accessed and treated via a percutaneous catheter (e.g., angioplasty). Such therapies have gained wide acceptance among patients and clinicians.


Some relatively common medical conditions may include or be the result of inefficiency, ineffectiveness, or complete failure of one or more of the valves within the heart. For example, failure of the aortic valve or the mitral valve can have a serious effect on a human and could lead to serious health conditions and/or death if not dealt with properly. Treatment of defective heart valves poses other challenges in that the treatment often requires the repair or outright replacement of the defective valve. Such therapies may be highly invasive to the patient. Disclosed herein are medical devices that may be used to deliver a medical device to a portion of the cardiovascular system in order to diagnose, treat, and/or repair the system. At least some of the medical devices disclosed herein may be used to deliver a replacement heart valve (e.g., a replacement aortic valve, replacement mitral valve, etc.). In addition, the devices disclosed herein may deliver the replacement heart valve percutaneously and, thus, may be much less invasive to the patient. The devices disclosed herein may also provide additional benefits as described in more detail below.


The figures illustrate selected components and/or arrangements of a medical device system 10, shown schematically in FIG. 1, for example. It should be noted that in any given figure, some features of the medical device system 10 may not be shown, or may be shown schematically, for simplicity. Additional details regarding some of the components of the medical device system 10 may be illustrated in other figures in greater detail.


The medical device system 10 may be used to deliver and/or deploy a variety of medical devices to a number of locations within the anatomy. In at least some embodiments, the medical device system 10 may include a replacement heart valve delivery system (e.g., a replacement aortic valve delivery system) that can be used for percutaneous delivery of a medical implant 16, such as a replacement/prosthetic heart valve. This, however, is not intended to be limiting as the medical device system 10 may also be used for other interventions including valve repair, valvuloplasty, delivery of an implantable medical device (e.g., such as a stent, graft, etc.), and the like, or other similar interventions.


The medical device system 10 may generally be described as a catheter system that includes an outer shaft 12, an inner shaft 14 (a portion of which is shown in FIG. 1) extending at least partially through a lumen of the outer shaft 12, and a medical implant 16 (e.g., a replacement heart valve implant) which may be coupled to the inner shaft 14 and disposed within an implant containment region 20 coupled to the outer shaft 12, the inner shaft 14 or both the outer shaft 12 and the inner shaft 14 during delivery of the medical implant 16. In some embodiments, a medical device handle 18 may be disposed at a proximal end of the outer shaft 12 and/or the inner shaft 14 and may include one or more actuation mechanisms associated therewith. In other words, a tubular member (e.g., the outer shaft 12, the inner shaft 14, etc.) may extend distally from the medical device handle 18. As will be described in greater detail below, the medical device handle 18 may be designed to manipulate the position of the outer shaft 12 relative to the inner shaft 14 and/or aid in the deployment of the medical implant 16.


In use, the medical device system 10 may be advanced percutaneously through the vasculature to a position adjacent to an area of interest and/or a treatment location. For example, in some embodiments, the medical device system 10 may be advanced through the vasculature to a position adjacent to a defective native valve (e.g., aortic valve, mitral valve, etc.). Alternative approaches to treat a defective aortic valve and/or other heart valve(s) are also contemplated with the medical device system 10. During delivery, the medical implant 16 may be generally disposed in an elongated and low profile “delivery” configuration within the implant containment region 20, as seen schematically in FIG. 1 for example. Once positioned, the outer shaft 12 and/or inner shaft 14 may be translated relative to each other and/or the medical implant 16 to expose (e.g., deploy) the medical implant 16. In some instances, a portion of the medical implant 16 may be self-expanding such that exposure of the medical implant 16 may deploy the medical implant 16. Alternatively, the medical implant 16 may be manipulated using the medical device handle 18 in order to translate the medical implant 16 into a deployed configuration suitable for implantation within the anatomy. When the medical implant 16 is suitably deployed within the anatomy, the medical device system 10 may be disconnected, detached, and/or released from the medical implant 16 and the medical device system 10 can be removed from the vasculature, leaving the medical implant 16 at the target tissue site.


As discussed above, the medical device system 10 may comprise an implant containment region 20 for accommodating the medical implant 16 in a collapsed form for introduction into the anatomy. The medical implant 16 may be a cardiac stent-valve. The delivery system 10 may be configured to permit delivery of the stent-valve 16 to a target site of implantation while the heart remains beating, for example, using a minimally invasive surgical and/or percutaneous procedure. In some embodiments, the delivery system 10 may be configured for introduction into the anatomical vascular system, and for advancement along the vasculature system to the desired site of implantation. For example, the delivery system 10 may be configured for introduction into the femoral artery, and guided retrograde via the descending aorta, aortic arch, and ascending aorta to the heart (sometimes called a transfemoral access). In other embodiments, the delivery system 10 may be insertable via the subclavian artery and guided retrograde to the heart (sometimes call transubclavian access). In other embodiments, the delivery system 10 may be inserted directly into a chamber of the heart such as a ventricle (for example, left ventricle) via a direct access route while the heart remains beating. For example, a direct access route may be through an aperture opened in the apex of the heart (sometimes called a transapical access).


It can be appreciated that during delivery and/or deployment of an implantable medical device (e.g., the medical implant 16), portions of the medical device system 10 may be required to be advanced through tortuous and/or narrow body lumens. Therefore, it may be desirable to utilize components and design medical delivery systems (e.g., such as the medical device system 10 and/or other medical devices) that reduce the profile of portions of the medical device while maintaining sufficient strength (compressive, torsional, etc.) and flexibility of the system as a whole.


In some examples, the stent-valve 16 may be expandable from a compressed or collapsed condition to an expanded condition, in order to anchor the stent-valve 16 at the implantation site. For example, the stent-valve 16 may form a friction and/or interference fit with respect to the native anatomy. Various shapes and geometries of stent-valve 16 may be used to fit the anatomy at the site of implantation. The stent-valve 16 may be self-expanding and/or may be configured to be expandable by an expandable member (for example, a balloon). Self-expanding stent-valves 16 may be constructed from shape-memory material, for example, a shape-memory metal alloy (e.g., nitinol). The self-expanding stent-valve 16 may be retained in its compressed state by being constrained within the containment region 20 of the delivery system 10. Upon at least partial release from the containment region 20, the released portion of the stent-valve 16 may be free to expand. Balloon expandable stent-valves 16 may also be made of shape-memory material, stainless steel, cobalt-chromium alloy or other materials. A non-limiting list of materials contemplated for one or more components of the stent delivery system 10 described herein is set forth below.



FIG. 2 illustrates an example first step in releasing (e.g., deploying) the stent-valve 16 from the medical device delivery system 10. As shown in FIG. 2, the containment region 20 of the medical device delivery system 10 may comprise a first sheath 22 and/or a second sheath 24. The first sheath 22 may be referred to as the distal sheath. The second sheath 24 may be referred to as the proximal sheath. Together, the first sheath 22 and the second sheath 24 may be translatable between a closed position (at least partially covering the stent-valve 16) and an open position (at least partially exposing at least a portion of the stent-valve 16). For example, FIG. 1 illustrates both the first sheath 22 and the second sheath 24 (collectively referred to as the containment region 20 above) in a closed position (wherein they are covering the stent-valve 16). Further, FIG. 2 illustrates that the first sheath 22 and the second sheath 24 may be translatable in opposite directions to an open position, as described above. For example, the first sheath 22 may be translatable in a distal direction (indicated by arrow 23 in FIG. 2) while the second sheath 24 may be translatable in a proximal direction (indicated by arrow 25 in FIG. 2).


Additionally, in some instances, the first sheath 22 and the second sheath 24 may translate independent of one another to release of the stent-valve 16 from the medical device delivery system 10. For example, FIG. 2 illustrates that translating the second sheath 24 in a proximal direction (e.g., indicated by arrow 25) while holding the first sheath 22 stationary, a portion 26 of the stent-valve 16 may be partially or fully released before a portion 28 of the stent-valve 16 covered by the first sheath 22 is partially or fully released. Further 3 illustrates that the portion 28 may subsequently be released by translation of the first sheath 22 in a distal direction (e.g., indicated by arrow 23).


Additionally, in some examples, the length of the second sheath 24 may be greater than the length of the first sheath 22. For example, the ratio of the second sheath 24 length divided by the first sheath 22 length may be at least 1.1, optionally at least 1.2, optionally at least 1.3, optionally at least 1.4, optionally at least 1.5, optionally at least 1.6, optionally at least 1.7, optionally at least 1.8, optionally at least 1.9, optionally at least 2.0, optionally at least 2.1, optionally at least 2.2, optionally at least 2.3, optionally at least 2.4, optionally at least 2.5, optionally at least 2.6, optionally at least 2.7, optionally at least 2.8, optionally at least 2.9, optionally at least 3, optionally at least 3.5, optionally at least 4 or optionally at least 4.5, or optionally at least 5.



FIG. 4 shows an enlarged portion of the distal region of the medical device delivery system 10 described above. For example, FIG. 4 illustrates the outer shaft 12 attached to the second (e.g., proximal) sheath 24 at a first connection point 30. Additionally, FIG. 4 illustrates the inner shaft 14 attached to a tip member 34 at a second connection region 32. Further, the tip member 34 may be attached to the first (e.g., distal) sheath 22. It can be appreciated that the tip member 34 may be designed with an atraumatic geometry, whereby the tip member 34 may include a tapered portion designed to ease navigation of the medical system 10 through challenging anatomical pathways. Additionally, FIG. 4 illustrates that the inner shaft 14 may include a lumen 36 through which a guidewire may be advanced.


It can be appreciated from FIG. 4 that as the outer shaft 12 translates with respect to the inner shaft 14, the second sheath 24 and the first sheath 22 will, correspondingly, translate with respect to one another. As will be described in greater detail below, as the outer shaft 12 and/or the inner shaft 14 are manipulated via the handle 18 (shown in FIG. 1), the second sheath 24 and/or the first sheath 22 may translate to release the medical implant 16.



FIG. 5 illustrates a cross-section of the handle 18 described above. The handle 18 may include a proximal end region 17 and a distal end region 19. FIG. 5 shows the outer shaft 12 (described above) and the inner shaft 14 (described above) entering the distal end region 19 of the handle 18. The outer shaft 12 may be coupled (e.g., attached) to a translation member 44. As shown in FIG. 5, the translation member 44 may be nested within a helical channel 46 disposed along a carriage 40. The carriage 40 may be coupled (e.g., attached) to a first actuator 38. It can be appreciated that the first actuator 38 may be designed to permit an operator to grasp and rotate the first actuator 38, whereby rotation of the first actuator 38 may correspondingly rotate the carriage 40. Further, rotation of the carriage 40 may rotate the helical channel 46, thereby causing the translation member 44 to translate parallel to the longitudinal axis of the handle 18. It can be appreciated that because the translation member 44 is attached to the outer shaft 12, translation of the translation member 44 will translate the outer shaft 12 correspondingly. Further, in some examples, the first actuator 38 may be designed to rotate in both a clockwise and a counterclockwise direction, thereby permitting an operator to selectively translate the outer shaft 12 in both a distal-to-proximal direction and also a proximal-to-distal direction.


Additionally, FIG. 5 illustrates that the handle 18 may include a second actuator 39 which is coupled to the inner shaft 14. Further, it can be appreciated the second actuator 39 may be coupled to the inner shaft 14 via a similar mechanism as described with respect to the first actuator 38. For example, the second actuator 39 may be coupled to the inner shaft 14 via a second translation member and second carriage 48. Further, rotation of the second actuator 39 (either in a clockwise or a counter-clockwise direction) may translate the inner shaft 14 in a distal-to-proximal direction or a proximal-to-distal direction (depending on the direction of rotation of the second actuator 39).


Further, as discussed above, because each of the outer shaft 12 and the inner shaft 14 are coupled to the second sheath 24 (not shown in FIG. 5, but described above) and the first sheath 22 (not shown in FIG. 5, but described above), manipulation of the first actuator 38 and/or the second actuator 39 may control the movement of the first sheath 22 and the second sheath 24 relative to one another. Additionally, it can be appreciated that it may be beneficial for either the first sheath 22 (not shown in FIG. 5, but described above) or the second sheath 24 (not shown in FIG. 5, but described above) to maintain its position while the second sheath 24 or the first sheath 22 is rotated. In other words, if an operator chooses to rotate the first actuator 38 (thereby translating the second sheath 24), the handle 18 may be designed such that the second carriage 48 resists any back-loading forces placed upon it by the translation of the second sheath 24 (and/or the deployment of the medical implant). Correspondingly, if the operator chooses to rotate the second actuator 39 (thereby translating the first sheath 22), the handle 18 may be designed such that the first carriage 40 resists any back-loading forces placed upon it by the translation of the first sheath 22 (and/or the deployment of the medical implant).


It can be appreciated, therefore, that, in some configurations, each of the first carriage 40 and second carriage 48 may need to be prevented from freely rotating (e.g., freely spinning) within the handle 18. In other words, it may be beneficial to design the handle 18 to include one or more components which impart a frictional resistance to the rotation of each of the first carriage 40 and the second carriage 48. It can be appreciated that this resistance may be translated to the first actuator 38 and the second actuator 39, thereby requiring an operator to overcome the resistive force in order to rotate either of the first actuator 38 and the second actuator 39. However, this resistance may provide increased control as an operator rotates either of the first actuator 38 and the second actuator 39 (when deploying the medical implant, for example).


To that end, FIG. 5 shows that the handle 18 may include a housing 42 positioned overtop the first carriage 40. In other words, the first carriage 40 may rotate inside an inner cavity of the housing 42. Further, FIG. 5 illustrates a cap 50 positioned along the distal end region of the handle 18. Specifically, the cap 50 may extend into the distal end of the inner cavity of the housing 42 and also into at least a portion of the distal end region of the first carriage 40. Additionally, FIG. 5 illustrates that the handle 18 may include a resistance member 66 (e.g., gasket, rubber gasket, etc.) positioned along the proximal end region of the cap 50. The resistance member 66 may exert an outward radial force upon the carriage 40, thereby imparting a resistive force (as described above) to the rotation of the first carriage 40. In other words, in order to rotate the first actuator 38, an operator may have to overcome the radially outward force the resistance member 66 imparts onto the first carriage 40.


While not shown in the figures, in some examples the medical device system 10 may include a third shaft (not shown for simplicity). The third shaft may be referred to as a “middle” shaft in some examples. The third shaft may be positioned between the inner shaft 14 and the outer shaft 12. Further, the third shaft may extend from the handle 18 to a positioned adjacent the stent-valve 16 (described above). In some examples, the stent-valve 16 may be coupled to the third shaft. For example, the stent-valve 16 may be coupled to the third shaft via a stent-valve holder (not shown in the figures). Additionally, the third shaft may be stationary with respect to the outer shaft 12, the inner shaft 14 or both the outer shaft 12 and the inner shaft 14. In other words, as the outer shaft 12 and/or the inner shaft 14 are actuated (as described above), the third shaft may remain stationary relative thereto. It can be appreciated that the third shaft may provide a stable, stationary “platform” on which to mount the stent-valve 16. For example, as the first sheath 22 and/or the second sheath 24 are translating with respect to one another (and the stent-valve 16), the third shaft may prevent the stent-valve 16 from sliding (e.g., dragging) as the first sheath 22 and/or the second sheath 24 are translated.


In some examples, the third shaft (described above) may be coupled to an inner spine tube 70 (shown in FIG. 5). The inner spine tube 70 may be coupled to the housing 42 via a screw 68. It can be appreciated that the inner spine tube 70 and/or the housing 42 may remain stationary as the outer shaft 12 and/or the inner shaft 14 are actuated by the first actuator 38 and the second actuator 39, respectively.



FIG. 6 shows a perspective view of the cap 50 described above. The cap 50 may include a proximal end region 52, a distal end region 54 and a medial region 64 extending therebetween. Further, the cap 50 may include a lumen 56 extending from the proximal end region 52 to the distal end region 54. FIG. 6 further illustrates that the cap 50 may include a groove 58 (e.g., channel, etc.) positioned along the proximal end region 52 of the cap 50. The groove 58 may extend circumferentially around the outer surface of the cap 50. As will be shown in greater detail in FIG. 7, the groove 58 may extend radially inward from an outer surface of the cap 50. Further, the groove 58 may be sized to accept the resistance member 66 (not shown in FIG. 6, but described above).



FIG. 6 further illustrates that the cap 50 may include an aperture 60 positioned within the medial region 64 of the cap 50. The aperture 60 may include a length “L.” In some examples, the aperture may extend longitudinally along the medial region 64. Additionally, the cap 50 may include a lip 62 positioned along the distal end region 54 of the cap 50. The lip 62 may extend circumferentially around and extend radially away from the outer surface of the cap 50. In some examples, the lip 62 may include one or more tapered and/or curved surfaces 63.



FIG. 7 illustrates a cross section of the cap 50 shown in FIG. 6. For example, FIG. 7 illustrates the groove 58 positioned along the proximal end region 52 of the cap 50. Further, FIG. 7 illustrates that the cap may include a wall thickness “Y” extending between the outer surface 61 and the inner surface 65 of the medial region 64. As shown in FIG. 7, the groove 58 may extend only partially into the wall thickness “Y” of the cap 50.


Additionally, FIG. 7 illustrates the aperture 60 having a length “L” as described above. As shown in FIG. 7, the aperture 60 may extend entirely through the wall thickness “Y” of the cap 50. However, this is not intended to be limiting. Rather, in some examples, the aperture may extend only partially through the wall thickness “Y” of the cap 50. Further, FIG. 7 illustrates the lip 62 extending radially outward from the outer surface 61 of the cap 50. As discussed above, the lip 62 may include one or more tapered and/or curved surfaces 63.


While the resistive force imparted by the resistance member 66 (described above) may provide increased control for an operator when deploying the medical implant, in some instances it may be desirable to selectively remove the resistive force imparted by the resistance member 66 on the second sheath 24 (via the connection of the first carriage 40 and the outer shaft 12). Removing the resistive force may permit the second sheath 24 to more freely translate relative to the first sheath 22.


For example, in some instances it may be desirable for an operator to engage (e.g., load) the medical implant into the first sheath 22 and/or the second sheath 24. Further, in order to properly position the implant within the first sheath 22 and/or the second sheath 24, the operator may be required to manipulate the first sheath 22 and/or the second sheath 24 relative to one another. It can be appreciated that loading the implant into the first sheath 22 and/or the second sheath 24 may require an operator to manipulate the first actuator 38 and/or the second actuator 39 at the handle (in order to adjust the spacing and position of the first sheath 22 and/or the second sheath 24 relative to one another). It can be appreciated that this may require the operator to physically move between the handle (at one end of the medical device system 10) and the first and second sheaths 22, 24 (at the opposite end of the medical device system 10). Therefore, it may be desirable to design the handle 18 such that an operator can selectively remove the resistive force imparted to the first actuator 38 (and subsequently the second sheath 24 via the carriage 40 and outer shaft 12). In other words, when the operator is loading the stent-valve, the resistive force may be removed, and subsequently, after loading (e.g., during insertion of the medical device system 10 into a patient's body) and/or when the operator is deploying the stent-valve, the resistive force may be applied.


To that end, FIG. 8 illustrates a detailed view of the distal end region 19 of the medical device system 10 in a “pre-deployment” configuration. The pre-deployment configuration may represent a configuration which is designed to load the stent-valve into the first sheath 22 and/or the second sheath 24 (e.g., a configuration in which an operator can manipulate the second sheath 24 without having to use the handle 18).



FIG. 8 illustrates that the cap 50 (described above) has been shifted in a distal direction a distance “X.” Further, FIG. 8 illustrates that shifting the cap 50 in a distal direction may correspondingly shift the resistance member 66 in a distal direction a distance “X.” Specifically, shifting the cap 50 in a distal direction may shift the resistance member 66 to a position in which it is free from (e.g., not contacting) the inner surface 74 of the first carriage 40. As shown in FIG. 8, the resistance member 66 is positioned adjacent to an inner surface 67 of the housing 42, thereby removing the resistive force from the carriage 40.



FIG. 8 further illustrates that the handle 18 may include a screw 68 which is positioned at least partially within the aperture 60 of the cap 50. It can be appreciated that the screw 68 may be prevent the cap from sliding all the way out the distal end of the housing 42. Additionally, it can be appreciated that the length of the aperture 60 (described as length “L” in FIG. 6 and FIG. 7 corresponds to the distance “X” the cap shifts in the distal direction.



FIG. 9 illustrates a detailed view of the distal end region 19 of the medical device system 10 in a “deployment” configuration. The deployment configuration may represent a configuration which is designed to advance the system through a blood vessel and/or deploy the medical implant at a target site, for example. FIG. 9 illustrates that the cap 50 (described above) has been shifted in a proximal direction (shown by the arrows 72) such that the resistance member 66 contacts the inner surface 74 of the carriage 40. As described above, in this configuration, the resistance member 66 may exert a radially outward force upon the inner surface 74 of the carriage 40, which, in turn, imparts a resistive force on the first actuator 38 (not shown in FIG. 9) and the second sheath 24 (not shown in FIG. 9).



FIG. 9 further illustrates that the lip 62 of the cap 50 may be shifted proximally such that it contacts the distal end of the housing 42. It can be appreciated that the lip 62 may be designed to permit an operator to engage a portion thereof, which may permit the operator to more easily shift the cap 50 between the pre-deployment configuration and the deployment configuration. Further, the lip 62 may have a profile (e.g., a beveled edge) that sits flush with the housing 42, in order to reduce the exposed profile of the cap 50. This feature may reduce the risk of the cap 50 being moved accidentally out of the proximal position (after the cap 50 has been placed in the proximal position for implanting a loaded stent-valve 16).



FIG. 10 illustrates another example cap 150. The cap 150 may be similar in form and function to the cap 50. For example, FIG. 10 shows that the cap 150 may include an aperture 160 positioned in the medial region 164 of the cap 150. However, as illustrated in FIG. 10, the aperture 160 may be offset from the longitudinal axis 155 of the cap 150. It can be appreciated that offsetting the aperture 160 from the longitudinal axis 155 of the cap 150 may allow the resistance member to be shifted between the pre-deployment configuration and the deployment configuration via “rotating” the cap 150. In other words, instead of requiring an operator to slide the cap 150 linearly along the longitudinal axis (as described in FIG. 8 and FIG. 9), the cap configuration shown in FIG. 10 may allow the resistance member 66 shift longitudinally as the cap 150 is being rotated.


As discussed above, in some instances it may be desirable for an operator to engage (e.g., load) a medical implant into the first sheath 22 and/or the second sheath 24. Further, in order to properly load a medical implant within the first sheath 22 and/or the second sheath 24, the operator may be required to manipulate (e.g., shift) the first sheath 22 and/or the second sheath 24 relative to one another. Therefore, in some instances, it may be beneficial for an operator to use a medical implant loading device (e.g., stent-valve loader) to help advance the first sheath 22 and/or the second sheath 24 relative to one another to cover and contain a medical implant within the first sheath 22 and/or the second sheath 24.



FIG. 11 illustrates an example medical implant loading device 80. The medical implant loading device 80 may be utilized by an operator to load a stent-valve 16 (shown above) into the first sheath 22 and/or the second sheath 24 prior to performing a medical procedure. FIG. 11 illustrates the medical implant loading device 80 in a configuration in which the medical implant 16 has already been loaded within the medical implant loading device 80. In other words, the first sheath 22, the second sheath 24 and the medical implant 16 are not visible in FIG. 11 (as they are positioned within the medical implant loading device 80).


However, FIG. 11 does illustrate that the medical implant loading device 80 may include a knob 82 coupled to a stem 84. FIG. 11 further illustrates the outer shaft 12 (described above) extending into the stem 84. Additionally, FIG. 11 shows that the implant loading device may include a sleeve 86 (visible through an aperture located in the stem 84). As will be described in greater detail below, it can be appreciated that the knob 82 may be rotated with respect to the stem 84. Rotation of the knob 82 with respect to the stem 84 may translate the first sheath 22 (described above) longitudinally with respect to the second sheath 24 (described above).



FIG. 12 illustrates an exploded view of the medical implant loading device 80 described above. For example, FIG. 12 illustrates the knob 82 and the stem 84. Further, FIG. 12 illustrates that the stem 84 may include a threaded portion 85 positioned along an end region thereof. As will be described in greater detail with respect to FIG. 13 below, the threaded portion 85 may be utilized to couple the knob 82 with the stem 84.



FIG. 12 further illustrates the sleeve 86 described above. As shown in FIG. 12, the sleeve 86 may separate into a first sleeve portion 87a and a second sleeve portion 87b. The first sleeve portion 87a and the second sleeve portion 87b may engage with one another in a “clamshell” configuration to form sleeve 86. The sleeve 86 may include proximal end region 91 and a distal end region 93. Additionally, FIG. 12 shows the outer shaft 12 extending through the stem 84. It can be appreciated that the stem 84 may be slid onto and overtop the first sheath 22 and the second sheath 24 such that the stem 84 is positioned proximal to the second sheath 24. Additionally, the sleeve 86 may be positioned within portion of an interior cavity of the stem 84 and/or the knob 82.


As described above, FIG. 12 further illustrates the outer shaft 12 coupled to the second sheath 24. In some examples, the distal end region of the outer shaft 12 may include a tapered region 92. The tapered region 92 may extend from the distal end region of the outer shaft 12 to the proximal end of the second sheath 24. Additionally, FIG. 12 illustrates the tip member 34 (described above) extending into an extension member 90. The extension member 90 may extend in a proximal-to-distal direction from the tip member 34.


As discussed above, the medical implant loading device 80 may be utilized to load a medical device (e.g., a stent-valve) into the first sheath 22 and/or the second sheath 24. The medical implant loading device 80 may be configured to apply an axial force to the first sheath 22 and/or the second sheath 24 as part of the loading operation. These axial forces may be designed to urge movement of the first sheath 22 and/or the second sheath 24 toward one another to cover all, or a portion of, the stent-valve 16. As discussed above, it can be appreciated that the ability to release the resistance of the first actuator 38 and/or the second actuator 39 (described above) within the handle (for example, by moving the cap 50 to its distal position as described above) may allow the first actuator 38 and/or the second actuator 39 to move freely as the knob 82 and/or the stem 84 are rotated (and, therefore, axially translated) with respect to one another. It can be appreciated that permitting the first actuator 38 and/or the second actuator 39 to move freely as the knob 82 shifts relative to the stem 84 may facilitate the loading of the stent-valve 16 (illustrated in FIGS. 1-4) by permitting the operator to remain at the distal end of the catheter, rather than having to physically move repeatedly between the handle and the distal end of the catheter to “mirror” the relative movement of the first sheath 22 and the second sheath 24 with the first actuator 38 and the second actuator 39.



FIG. 13 illustrates a cross-section of the medical implant loading device 80. For simplicity, FIG. 13 does not show a medical implant positioned between the first sheath 22 and the second sheath 24. However, it can be appreciated that an operator may position the medical implant (e.g., a stent-valve 16) between the first sheath 22 and the second sheath 24 prior to moving the first sheath 22 relative to the second sheath 24 via the medical implant loading device 80. As described above, in some instances the medical implant may be coupled to a third shaft (described above), whereby the third shaft may extend between the first sheath 22 and the second sheath 24.


It can be appreciated from FIG. 13 that rotation of the knob 82 may apply a proximally-directed force to the first sheath 22 (via the extension member 90). For example, the knob 82 may include an inner surface profile which engages the extension member 90. Further, FIG. 13 illustrates that the knob 82 may include a threaded portion 89 designed to mate with the threaded portion 85 along the distal end region of the stem 84.



FIG. 13 shows that the extension member 90 may abut (directly or indirectly) the tip member 34 (or any other member attached to the tip member 34) of the first sheath 22. Further, it can be appreciated from FIG. 13 that rotation of the stem 84 may apply a distally-directed force to the second sheath 24 via sleeve 86. FIG. 13 illustrates that the sleeve 86 (including the first sleeve portion 87a and the second sleeve portion 87b) may be positioned within the stem 84. Further, the second sheath 24 and all (or a portion of) the first sheath 22 may be positioned within the sleeve 86. Additionally, FIG. 13 illustrates that the distal end region 91 of the sleeve 86 may include a (e.g. tapered) surface which engages the tapered portion 92 of the outer shaft 12.


As described above, an operator may rotate either the knob 82 and/or the stem 84 to progressively apply an axially compressive force between the knob 82 and the stem 84 to move the first sheath 22 and/or the second sheath 24 closer toward one another. This may permit an operator to load a stent-valve into the first sheath 22 and/or the second sheath 24 while working primarily at the distal end of the catheter. The medical implant loading device 80 may apply the axial forces at the distal end to close the first sheath 22 and/or the second sheath 24 over the stent valve as part of the loading operation. As described above, it can be appreciated that the ability to release the resistance of the first actuator 38 and/or the second actuator 39 within the handle 18 (by shifting the cap 50 to its distal position, for example) and may improve the speed and efficiency in which an operator may load a medical implant prior to performing a medical procedure.


The materials that can be used for the various components of the medical devices and/or systems disclosed herein may include those commonly associated with medical devices. For simplicity purposes, the following discussion makes reference to the medical device delivery system 10 including the various components of the medical device delivery system 10.


The medical device delivery system 10 may be made from a metal, metal alloy, polymer (some examples of which are disclosed below), a metal-polymer composite, ceramics, combinations thereof, and the like, or other suitable material. Some examples of suitable polymers may include polytetrafluoroethylene (PTFE), ethylene tetrafluoroethylene (ETFE), fluorinated ethylene propylene (FEP), polyoxymethylene (POM, for example, DELRIN® available from DuPont), polyether block ester, polyurethane (for example, Polyurethane 85A), polypropylene (PP), polyvinylchloride (PVC), polyether-ester (for example, ARNITEL® available from DSM Engineering Plastics), ether or ester based copolymers (for example, butylene/poly(alkylene ether) phthalate and/or other polyester elastomers such as HYTREL® available from DuPont), polyamide (for example, DURETHAN® available from Bayer or CRISTAMID® available from Elf Atochem), elastomeric polyamides, block polyamide/ethers, polyether block amide (PEBA, for example available under the trade name PEBAX®), ethylene vinyl acetate copolymers (EVA), silicones, polyethylene (PE), high density polyethylene (HDPE), polyester, Marlex high-density polyethylene, Marlex low-density polyethylene, linear low density polyethylene (for example REXELL®), ultra-high molecular weight (UHMW) polyethylene, polypropylene, polybutylene terephthalate (PBT), polyethylene terephthalate (PET), polytrimethylene terephthalate, polyethylene naphthalate (PEN), polyetheretherketone (PEEK), polyimide (PI), polyetherimide (PEI), polyphenylene sulfide (PPS), polyphenylene oxide (PPO), poly paraphenylene terephthalamide (for example, KEVLAR®), polysulfone, nylon, nylon-12 (such as GRILAMID® available from EMS American Grilon), perfluoro(propyl vinyl ether) (PFA), ethylene vinyl alcohol, polyolefin, polystyrene, epoxy, polyvinylidene chloride (PVdC), poly(styrene-b-isobutylene-b-styrene) (for example, SIBS and/or SIBS 50A), polycarbonates, ionomers, biocompatible polymers, other suitable materials, or mixtures, combinations, copolymers thereof, polymer/metal composites, and the like. In some embodiments the sheath can be blended with a liquid crystal polymer (LCP).


Some examples of suitable metals and metal alloys include stainless steel, such as 304V, 304L, and 316LV stainless steel; mild steel; nickel-titanium alloy such as linear-elastic and/or super-elastic nitinol; other nickel alloys such as nickel-chromium-molybdenum alloys (e.g., UNS: N06625 such as INCONEL® 625, UNS: N06022 such as HASTELLOY® C-22®, UNS: N10276 such as HASTELLOY® C276®, other HASTELLOY® alloys, and the like), nickel-copper alloys (e.g., UNS: N04400 such as MONEL® 400, NICKELVAC® 400, NICORROS® 400, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nickel-molybdenum alloys (e.g., UNS: N10665 such as HASTELLOY® ALLOY B2®), other nickel-chromium alloys, other nickel-molybdenum alloys, other nickel-cobalt alloys, other nickel-iron alloys, other nickel-copper alloys, other nickel-tungsten or tungsten alloys, and the like; cobalt-chromium alloys; cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like); platinum enriched stainless steel; titanium; combinations thereof; and the like; or any other suitable material.


In at least some embodiments, portions or all of the medical device delivery system 10 may also be doped with, made of, or otherwise include a radiopaque material. Radiopaque materials are understood to be materials capable of producing a relatively bright image on a fluoroscopy screen or another imaging technique during a medical procedure. This relatively bright image aids the user of the shaft in determining its location. Some examples of radiopaque materials can include, but are not limited to, gold, platinum, palladium, tantalum, tungsten alloy, polymer material loaded with a radiopaque filler, and the like. Additionally, other radiopaque marker bands and/or coils may also be incorporated into the design of the medical device delivery system 10 to achieve the same result.


In some embodiments, a degree of Magnetic Resonance Imaging (MRI) compatibility is imparted into the shaft. For example, the medical device delivery system 10 may include a material that does not substantially distort the image and create substantial artifacts (e.g., gaps in the image). Certain ferromagnetic materials, for example, may not be suitable because they may create artifacts in an MRI image. The medical device delivery system 10 may also be made from a material that the MRI machine can image. Some materials that exhibit these characteristics include, for example, tungsten, cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nitinol, and the like, and others.


It should be understood that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of steps without exceeding the scope of the disclosure. This may include, to the extent that it is appropriate, the use of any of the features of one example embodiment being used in other embodiments. The disclosure's scope is, of course, defined in the language in which the appended claims are expressed.

Claims
  • 1. A delivery system for an implantable medical device, comprising: an outer shaft having a distal end region, a proximal end region and a lumen extending therebetween;a handle coupled to the proximal end region of the outer shaft, wherein the handle includes a first actuator, a carriage and a housing,a cap coupled to the handle; anda resistance member disposed along a portion of the cap;wherein the cap is configured to shift between a first configuration and a deployment configuration, and wherein the carriage is free from the resistance member in the first configuration and wherein the resistance member contacts the carriage in the deployment configuration;wherein the resistance member contacts an inner surface along a distal end region of the housing in the first configuration.
  • 2. The delivery system of claim 1, wherein the resistance member contacts an inner surface along a distal end region of the carriage in the deployment configuration.
  • 3. The delivery system of claim 1, wherein the carriage is configured to rotate, and wherein the resistance member is configured to increase a rotational force required to rotate the carriage in the deployment configuration.
  • 4. The delivery system of claim 1, wherein the cap includes a circumferential groove positioned along a proximal end region thereof, wherein at least a portion of the resistance member is positioned along the groove.
  • 5. The delivery system of claim 1, further comprising an implant loading device positioned adjacent the distal end region of the outer shaft.
  • 6. The delivery system of claim 5, wherein the cap includes an inner surface, an outer surface and a wall extending therebetween, and wherein the cap includes an aperture extending through a wall of the cap.
  • 7. The delivery system of claim 6, wherein the aperture includes a length, and wherein the length of the aperture corresponds to a distance along which the cap shifts between the first configuration and the deployment configuration.
  • 8. The delivery system of claim 6, wherein the aperture is aligned along a longitudinal axis of the cap.
  • 9. The delivery system of claim 6, wherein the aperture is offset from a longitudinal axis of the cap.
  • 10. The delivery system of claim 9, wherein rotating the cap shifts it between the first configuration and the deployment configuration.
  • 11. The delivery system of claim 1, wherein the cap includes a circumferential lip extending circumferentially along a distal end region thereof.
  • 12. The delivery system of claim 11, wherein the lip extends radially away from an outer surface of the cap.
  • 13. The delivery system of claim 1, wherein the resistance member is configured to exert a radially outward force on an inner surface of the carriage in the deployment configuration.
  • 14. A delivery system for an implantable medical device, comprising: an outer shaft having a distal end region, a proximal end region and a lumen extending therebetween;a handle coupled to the proximal end region of the outer shaft, wherein the handle includes a first actuator, a carriage and a housing;a cap coupled to the handle; anda resistance member disposed along a portion of the cap,wherein the cap is configured to shift between a first configuration and a deployment configuration, and wherein the carriage is free from the resistance member in the first configuration and wherein the resistance member exerts a radially outward force upon the carriage in the deployment configuration;wherein the resistance member contacts an inner surface along a distal end region of the housing in the first configuration.
  • 15. The delivery system of claim 14, wherein the resistance member contacts an inner surface along a distal end region of the carriage in the deployment configuration.
  • 16. The delivery system of claim 14, wherein the carriage is configured to rotate, and wherein the resistance member is configured to increase a rotational force required to rotate the carriage in the deployment configuration.
  • 17. A method of manufacturing an implantable medical device, the method comprising: engaging the implantable medical device with a medical device delivery system in a pre-deployment configuration, the medical device delivery system including: an outer shaft having a distal end region, a proximal end region and a lumen extending therebetween;a handle coupled to the proximal end region of the outer shaft, wherein the handle includes a first actuator, a carriage and a housing;a cap coupled to the handle; anda resistance member disposed along a portion of the cap,wherein the resistance member contacts an inner surface along a distal end region of the housing in the pre-deployment configuration;converting the medical device delivery system from the pre-deployment configuration to a deployment configuration, wherein converting the medical device delivery system includes shifting the cap from a first position to a second position,wherein the carriage is free from the resistance member when the cap is in the first position and wherein the resistance member contacts the carriage when the cap is in the second position.
  • 18. The method of claim 17, wherein the implantable medical device includes an implantable heart valve.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority to U.S. Provisional Application Ser. No. 62/777,487, filed Dec. 10, 2018, the entirety of which is incorporated herein by reference.

US Referenced Citations (932)
Number Name Date Kind
15192 Peale Jun 1856 A
2682057 Lord Jun 1954 A
2701559 Cooper Feb 1955 A
2832078 Williams Apr 1958 A
3029819 Starks Apr 1962 A
3099016 Lowell Jul 1963 A
3113586 Edmark Dec 1963 A
3130418 Head et al. Apr 1964 A
3143742 Cromie Aug 1964 A
3221006 Moore et al. Nov 1965 A
3334629 Cohn Aug 1967 A
3365728 Edwards et al. Jan 1968 A
3367364 Cruz et al. Feb 1968 A
3409013 Henry Nov 1968 A
3445916 Schulte May 1969 A
3540431 Mobin-Uddin Nov 1970 A
3548417 Kischer et al. Dec 1970 A
3570014 Hancock Mar 1971 A
3587115 Shiley Jun 1971 A
3592184 Watkins et al. Jul 1971 A
3628535 Ostrowsky et al. Dec 1971 A
3642004 Osthagen et al. Feb 1972 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Goodenough et al. Feb 1973 A
3725961 Magovern et al. Apr 1973 A
3755823 Hancock Sep 1973 A
3795246 Sturgeon Mar 1974 A
3839741 Haller Oct 1974 A
3868956 Alfidi et al. Mar 1975 A
3874388 King et al. Apr 1975 A
3983581 Angell et al. Oct 1976 A
3997923 Possis Dec 1976 A
4035849 Angell et al. Jul 1977 A
4056854 Boretos et al. Nov 1977 A
4084268 Ionescu et al. Apr 1978 A
4106129 Carpentier et al. Aug 1978 A
4222126 Boretos et al. Sep 1980 A
4233690 Akins Nov 1980 A
4265694 Boretos et al. May 1981 A
4291420 Reul Sep 1981 A
4297749 Davis et al. Nov 1981 A
4323358 Lentz et al. Apr 1982 A
4326306 Poler Apr 1982 A
4339831 Johnson Jul 1982 A
4343048 Ross et al. Aug 1982 A
4345340 Rosen Aug 1982 A
4373216 Klawitter Feb 1983 A
4406022 Roy Sep 1983 A
4423809 Mazzocco Jan 1984 A
4425908 Simon Jan 1984 A
4470157 Love Sep 1984 A
4484579 Meno et al. Nov 1984 A
4501030 Lane Feb 1985 A
4531943 Tassel et al. Jul 1985 A
4535483 Klawitter et al. Aug 1985 A
4574803 Storz Mar 1986 A
4580568 Gianturco Apr 1986 A
4592340 Boyles Jun 1986 A
4602911 Ahmadi et al. Jul 1986 A
4605407 Black et al. Aug 1986 A
4610688 Silvestrini et al. Sep 1986 A
4612011 Kautzky Sep 1986 A
4617932 Kornberg Oct 1986 A
4643732 Pietsch et al. Feb 1987 A
4647283 Carpentier et al. Mar 1987 A
4648881 Carpentier et al. Mar 1987 A
4655218 Kulik et al. Apr 1987 A
4655771 Wallsten et al. Apr 1987 A
4662885 DiPisa May 1987 A
4665906 Jervis May 1987 A
4680031 Alonso Jul 1987 A
4692164 Dzemeshkevich et al. Sep 1987 A
4705516 Barone et al. Nov 1987 A
4710192 Liotta et al. Dec 1987 A
4733665 Palmaz et al. Mar 1988 A
4755181 Igoe Jul 1988 A
4759758 Gabbay Jul 1988 A
4777951 Cribier et al. Oct 1988 A
4787899 Lazarus Nov 1988 A
4787901 Baykut Nov 1988 A
4796629 Grayzel Jan 1989 A
4819751 Shimada et al. Apr 1989 A
4829990 Thuroff et al. May 1989 A
4834755 Silvestrini et al. May 1989 A
4851001 Faheri Jul 1989 A
4856516 Hillstead Aug 1989 A
4865600 Carpentier et al. Sep 1989 A
4872874 Taheri Oct 1989 A
4873978 Ginsburg Oct 1989 A
4878495 Grayzel Nov 1989 A
4878906 Lindemann et al. Nov 1989 A
4883458 Shiber Nov 1989 A
4885005 Nashef et al. Dec 1989 A
4909252 Goldberger Mar 1990 A
4917102 Miller et al. Apr 1990 A
4922905 Strecker May 1990 A
4927426 Dretler May 1990 A
4954126 Wallsten Sep 1990 A
4966604 Reiss Oct 1990 A
4969890 Sugita et al. Nov 1990 A
4979939 Shiber Dec 1990 A
4986830 Owens et al. Jan 1991 A
4994077 Dobben Feb 1991 A
5002556 Ishida et al. Mar 1991 A
5002559 Tower Mar 1991 A
5007896 Shiber Apr 1991 A
5026366 Leckrone Jun 1991 A
5032128 Alonso Jul 1991 A
5037434 Lane Aug 1991 A
5047041 Samuels Sep 1991 A
5064435 Porter Nov 1991 A
5080668 Bolz et al. Jan 1992 A
5085635 Cragg Feb 1992 A
5089015 Ross Feb 1992 A
5122154 Rhodes Jun 1992 A
5132473 Furutaka et al. Jul 1992 A
5141494 Danforth et al. Aug 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5159937 Tremulis Nov 1992 A
5161547 Tower Nov 1992 A
5163953 Vince Nov 1992 A
5167628 Boyles Dec 1992 A
5209741 Spaeth May 1993 A
5215541 Nashef et al. Jun 1993 A
5217481 Barbara Jun 1993 A
5217483 Tower Jun 1993 A
5238004 Sahatjian et al. Aug 1993 A
5258023 Reger Nov 1993 A
5258042 Mehta Nov 1993 A
5282847 Trescony et al. Feb 1994 A
5295958 Shturman Mar 1994 A
5332402 Teitelbaum Jul 1994 A
5336258 Quintero et al. Aug 1994 A
5350398 Pavcnik et al. Sep 1994 A
5360444 Kusuhara Nov 1994 A
5370685 Stevens Dec 1994 A
5389106 Tower Feb 1995 A
5397351 Pavcnik et al. Mar 1995 A
5409019 Wilk Apr 1995 A
5411552 Andersen et al. May 1995 A
5425739 Jessen Jun 1995 A
5425762 Muller Jun 1995 A
5431676 Dubrul et al. Jul 1995 A
5443446 Shturman Aug 1995 A
5443449 Buelna Aug 1995 A
5443477 Marin et al. Aug 1995 A
5443495 Buscemi et al. Aug 1995 A
5443499 Schmitt Aug 1995 A
5469868 Reger Nov 1995 A
5476506 Lunn Dec 1995 A
5476510 Eberhardt et al. Dec 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5480424 Cox Jan 1996 A
5489297 Duran Feb 1996 A
5500014 Quijano et al. Mar 1996 A
5507767 Maeda et al. Apr 1996 A
5522881 Lentz Jun 1996 A
5534007 Germain et al. Jul 1996 A
5545133 Burns et al. Aug 1996 A
5545209 Roberts et al. Aug 1996 A
5545211 An et al. Aug 1996 A
5545214 Stevens Aug 1996 A
5549665 Vesely et al. Aug 1996 A
5554185 Block et al. Sep 1996 A
5571175 Vanney et al. Nov 1996 A
5571215 Sterman et al. Nov 1996 A
5573520 Schwartz et al. Nov 1996 A
5575818 Pinchuk Nov 1996 A
5591185 Kilmer et al. Jan 1997 A
5591195 Taheri et al. Jan 1997 A
5607464 Trescony et al. Mar 1997 A
5609626 Quijano et al. Mar 1997 A
5628784 Strecker May 1997 A
5645559 Hachtman et al. Jul 1997 A
5653745 Trescony et al. Aug 1997 A
5662671 Barbut et al. Sep 1997 A
5667523 Bynon et al. Sep 1997 A
5674277 Freitag Oct 1997 A
5681345 Euteneuer Oct 1997 A
5693083 Baker et al. Dec 1997 A
5693088 Lazarus Dec 1997 A
5693310 Gries et al. Dec 1997 A
5695498 Tower Dec 1997 A
5709713 Evans et al. Jan 1998 A
5713951 Garrison et al. Feb 1998 A
5713953 Vallana et al. Feb 1998 A
5716370 Williamson et al. Feb 1998 A
5716417 Girard et al. Feb 1998 A
5720391 Dohm et al. Feb 1998 A
5725549 Lam Mar 1998 A
5728068 Leone et al. Mar 1998 A
5733325 Robinson et al. Mar 1998 A
5735842 Krueger et al. Apr 1998 A
5749890 Shaknovich May 1998 A
5755783 Stobie et al. May 1998 A
5756476 Epstein et al. May 1998 A
5769812 Stevens et al. Jun 1998 A
5769882 Fogarty et al. Jun 1998 A
5772609 Nguyen et al. Jun 1998 A
5776188 Shepherd et al. Jul 1998 A
5782904 White et al. Jul 1998 A
5800456 Maeda et al. Sep 1998 A
5800531 Cosgrove et al. Sep 1998 A
5807405 Vanney et al. Sep 1998 A
5817126 Imran Oct 1998 A
5824037 Fogarty et al. Oct 1998 A
5824041 Lenker et al. Oct 1998 A
5824043 Cottone Oct 1998 A
5824053 Khosravi et al. Oct 1998 A
5824055 Spiridigliozzi et al. Oct 1998 A
5824056 Rosenberg Oct 1998 A
5824064 Taheri Oct 1998 A
5840081 Andersen et al. Nov 1998 A
5843158 Lenker et al. Dec 1998 A
5843161 Solovay Dec 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5855602 Angell Jan 1999 A
5860966 Tower Jan 1999 A
5860996 Urban et al. Jan 1999 A
5861024 Rashidi Jan 1999 A
5861028 Angell Jan 1999 A
5868783 Tower Feb 1999 A
5876419 Carpenter et al. Mar 1999 A
5876448 Thompson et al. Mar 1999 A
5885228 Rosenman et al. Mar 1999 A
5888201 Stinson et al. Mar 1999 A
5891191 Stinson Apr 1999 A
5895399 Barbut et al. Apr 1999 A
5906619 Olson et al. May 1999 A
5907893 Zadno-Azizi et al. Jun 1999 A
5910154 Tsugita et al. Jun 1999 A
5911734 Tsugita et al. Jun 1999 A
5925063 Khosravi Jul 1999 A
5944738 Amplatz et al. Aug 1999 A
5954766 Zadno-Azizi et al. Sep 1999 A
5957949 Leonhardt et al. Sep 1999 A
5968070 Bley et al. Oct 1999 A
5984957 Laptewicz et al. Nov 1999 A
5984959 Robertson et al. Nov 1999 A
5993469 McKenzie et al. Nov 1999 A
5997557 Barbut et al. Dec 1999 A
6010522 Barbut et al. Jan 2000 A
6015431 Thornton et al. Jan 2000 A
6022370 Tower Feb 2000 A
6027520 Tsugita et al. Feb 2000 A
6027525 Suh et al. Feb 2000 A
6042598 Tsugita et al. Mar 2000 A
6042607 Williamson et al. Mar 2000 A
6051014 Jang Apr 2000 A
6059827 Fenton May 2000 A
6074418 Buchanan et al. Jun 2000 A
6093203 Uflacker Jul 2000 A
6096074 Pedros Aug 2000 A
6110198 Fogarty et al. Aug 2000 A
6123723 Konya et al. Sep 2000 A
6132473 Williams et al. Oct 2000 A
6139510 Palermo Oct 2000 A
6142987 Tsugita Nov 2000 A
6146366 Schachar Nov 2000 A
6162245 Jayaraman Dec 2000 A
6165200 Tsugita et al. Dec 2000 A
6165209 Patterson et al. Dec 2000 A
6168579 Tsugita Jan 2001 B1
6168614 Andersen et al. Jan 2001 B1
6171327 Daniel et al. Jan 2001 B1
6171335 Wheatley et al. Jan 2001 B1
6179859 Bates et al. Jan 2001 B1
6187016 Hedges et al. Feb 2001 B1
6197053 Cosgrove et al. Mar 2001 B1
6200336 Pavcnik et al. Mar 2001 B1
6206911 Milo Mar 2001 B1
6214036 Letendre et al. Apr 2001 B1
6221006 Dubrul et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6221096 Aiba et al. Apr 2001 B1
6221100 Strecker Apr 2001 B1
6231544 Tsugita et al. May 2001 B1
6231551 Barbut May 2001 B1
6241757 An et al. Jun 2001 B1
6245102 Jayaraman Jun 2001 B1
6251135 Stinson et al. Jun 2001 B1
6258114 Konya et al. Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6258120 McKenzie et al. Jul 2001 B1
6258129 Dybdal et al. Jul 2001 B1
6267783 Letendre et al. Jul 2001 B1
6270513 Tsugita et al. Aug 2001 B1
6277555 Duran et al. Aug 2001 B1
6299637 Shaolian et al. Oct 2001 B1
6302906 Goicoechea et al. Oct 2001 B1
6306164 Kujawski Oct 2001 B1
6309417 Spence et al. Oct 2001 B1
6312465 Griffin et al. Nov 2001 B1
6319281 Patel Nov 2001 B1
6327772 Zadno-Azizi et al. Dec 2001 B1
6336934 Gilson et al. Jan 2002 B1
6336937 Vonesh et al. Jan 2002 B1
6338735 Stevens Jan 2002 B1
6346116 Brooks et al. Feb 2002 B1
6348063 Yassour et al. Feb 2002 B1
6352554 Paulis Mar 2002 B2
6352708 Duran et al. Mar 2002 B1
6361545 Macoviak et al. Mar 2002 B1
6363938 Saadat et al. Apr 2002 B2
6364895 Greenhalgh Apr 2002 B1
6371970 Khosravi et al. Apr 2002 B1
6371983 Lane Apr 2002 B1
6379383 Palmaz et al. Apr 2002 B1
6387122 Cragg May 2002 B1
6398807 Chouinard et al. Jun 2002 B1
6402736 Brown et al. Jun 2002 B1
6409750 Hyodoh et al. Jun 2002 B1
6416510 Altman et al. Jul 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6468303 Amplatz et al. Oct 2002 B1
6468660 Ogle et al. Oct 2002 B2
6475239 Campbell et al. Nov 2002 B1
6482228 Norred Nov 2002 B1
6485501 Green Nov 2002 B1
6485502 Michael et al. Nov 2002 B2
6488704 Connelly et al. Dec 2002 B1
6494909 Greenhalgh Dec 2002 B2
6503272 Duerig et al. Jan 2003 B2
6508803 Horikawa et al. Jan 2003 B1
6508833 Pavcnik et al. Jan 2003 B2
6527800 McGuckin et al. Mar 2003 B1
6530949 Konya et al. Mar 2003 B2
6530952 Vesely Mar 2003 B2
6537297 Tsugita et al. Mar 2003 B2
6540768 Diaz et al. Apr 2003 B1
6540782 Snyders Apr 2003 B1
6562058 Seguin et al. May 2003 B2
6569196 Vesely May 2003 B1
6572643 Gharibadeh Jun 2003 B1
6585766 Huynh et al. Jul 2003 B1
6592546 Barbut et al. Jul 2003 B1
6592614 Lenker et al. Jul 2003 B2
6605112 Moll et al. Aug 2003 B1
6610077 Hancock et al. Aug 2003 B1
6616682 Joergensen et al. Sep 2003 B2
6622604 Chouinard et al. Sep 2003 B1
6623518 Thompson et al. Sep 2003 B2
6623521 Steinke et al. Sep 2003 B2
6626938 Butaric et al. Sep 2003 B1
6632243 Zadno-Azizi et al. Oct 2003 B1
6635068 Dubrul et al. Oct 2003 B1
6635079 Unsworth et al. Oct 2003 B2
6635080 Lauterjung et al. Oct 2003 B1
6652571 White et al. Nov 2003 B1
6652578 Bailey et al. Nov 2003 B2
6663588 DuBois et al. Dec 2003 B2
6663663 Kim et al. Dec 2003 B2
6663667 Dehdashtian et al. Dec 2003 B2
6669724 Park et al. Dec 2003 B2
6673089 Yassour et al. Jan 2004 B1
6673109 Cox Jan 2004 B2
6676668 Mercereau et al. Jan 2004 B2
6676692 Rabkin et al. Jan 2004 B2
6676698 McGuckin et al. Jan 2004 B2
6682543 Barbut et al. Jan 2004 B2
6682558 Tu et al. Jan 2004 B2
6682559 Myers et al. Jan 2004 B2
6685739 DiMatteo et al. Feb 2004 B2
6689144 Gerberding Feb 2004 B2
6689164 Seguin Feb 2004 B1
6692512 Jang Feb 2004 B2
6695864 Macoviak et al. Feb 2004 B2
6695865 Boyle et al. Feb 2004 B2
6702851 Chinn et al. Mar 2004 B1
6712842 Gifford et al. Mar 2004 B1
6712843 Elliott Mar 2004 B2
6714842 Ito Mar 2004 B1
6719789 Cox Apr 2004 B2
6723116 Taheri Apr 2004 B2
6729356 Baker et al. May 2004 B1
6730118 Spenser et al. May 2004 B2
6730377 Wang May 2004 B2
6733525 Yang et al. May 2004 B2
6736846 Cox May 2004 B2
6752828 Thornton Jun 2004 B2
6755854 Gillick et al. Jun 2004 B2
6758855 Fulton et al. Jul 2004 B2
6764503 Ishimaru Jul 2004 B1
6764509 Chinn et al. Jul 2004 B2
6767345 Germain et al. Jul 2004 B2
6769434 Liddicoat et al. Aug 2004 B2
6773454 Wholey et al. Aug 2004 B2
6773456 Gordon et al. Aug 2004 B1
6776791 Stallings et al. Aug 2004 B1
6786925 Schoon et al. Sep 2004 B1
6790229 Berreklouw Sep 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6790237 Stinson Sep 2004 B2
6792979 Konya et al. Sep 2004 B2
6797002 Spence et al. Sep 2004 B2
6814746 Thompson et al. Nov 2004 B2
6814754 Greenhalgh Nov 2004 B2
6821297 Snyders Nov 2004 B2
6824041 Grieder et al. Nov 2004 B2
6830585 Artof et al. Dec 2004 B1
6837901 Rabkin et al. Jan 2005 B2
6840957 DiMatteo et al. Jan 2005 B2
6843802 Villalobos et al. Jan 2005 B1
6849085 Marton Feb 2005 B2
6863668 Gillespie et al. Mar 2005 B2
6863688 Ralph et al. Mar 2005 B2
6866650 Stevens et al. Mar 2005 B2
6866669 Buzzard et al. Mar 2005 B2
6872223 Roberts et al. Mar 2005 B2
6872226 Cali et al. Mar 2005 B2
6875231 Anduiza et al. Apr 2005 B2
6881220 Edwin et al. Apr 2005 B2
6887266 Williams et al. May 2005 B2
6890340 Duane May 2005 B2
6893459 Macoviak May 2005 B1
6893460 Spenser et al. May 2005 B2
6896690 Lambrecht et al. May 2005 B1
6905743 Chen et al. Jun 2005 B1
6908481 Cribier Jun 2005 B2
6911036 Douk et al. Jun 2005 B2
6911040 Johnson et al. Jun 2005 B2
6911043 Myers et al. Jun 2005 B2
6936058 Forde et al. Aug 2005 B2
6936067 Buchanan Aug 2005 B2
6939352 Buzzard et al. Sep 2005 B2
6951571 Srivastava Oct 2005 B1
6953332 Kurk et al. Oct 2005 B1
6964673 Tsugita et al. Nov 2005 B2
6969395 Eskuri Nov 2005 B2
6972025 WasDyke Dec 2005 B2
6974464 Quijano et al. Dec 2005 B2
6974474 Pavcnik et al. Dec 2005 B2
6974476 McGuckin et al. Dec 2005 B2
6979350 Moll et al. Dec 2005 B2
6984242 Campbell et al. Jan 2006 B2
6989027 Mien et al. Jan 2006 B2
7004176 Lau Feb 2006 B2
7011681 Vesely Mar 2006 B2
7018406 Seguin et al. Mar 2006 B2
7025791 Levine et al. Apr 2006 B2
7037331 Mitelberg et al. May 2006 B2
7041132 Quijano et al. May 2006 B2
7044966 Svanidze et al. May 2006 B2
7097658 Oktay Aug 2006 B2
7108715 Lawrence-Brown et al. Sep 2006 B2
7122020 Mogul Oct 2006 B2
7125418 Duran et al. Oct 2006 B2
7141063 White et al. Nov 2006 B2
7147663 Berg et al. Dec 2006 B1
7166097 Barbut Jan 2007 B2
7175652 Cook et al. Feb 2007 B2
7175653 Gaber Feb 2007 B2
7175654 Bonsignore et al. Feb 2007 B2
7175656 Khairkhahan Feb 2007 B2
7189258 Johnson et al. Mar 2007 B2
7191018 Gielen et al. Mar 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7235093 Gregorich Jun 2007 B2
7252682 Seguin Aug 2007 B2
7258696 Rabkin et al. Aug 2007 B2
7261732 Justino Aug 2007 B2
7264632 Wright et al. Sep 2007 B2
7267686 DiMatteo et al. Sep 2007 B2
7276078 Spenser et al. Oct 2007 B2
7322932 Xie et al. Jan 2008 B2
7326236 Andreas et al. Feb 2008 B2
7329279 Haug et al. Feb 2008 B2
7331993 White Feb 2008 B2
7374560 Ressemann et al. May 2008 B2
7381219 Salahieh et al. Jun 2008 B2
7381220 Macoviak et al. Jun 2008 B2
7399315 Iobbi Jul 2008 B2
7445631 Salahieh et al. Nov 2008 B2
7470285 Nugent et al. Dec 2008 B2
7491232 Bolduc et al. Feb 2009 B2
7510574 Lê et al. Mar 2009 B2
7524330 Berreklouw Apr 2009 B2
7530995 Quijano et al. May 2009 B2
7544206 Cohn Jun 2009 B2
7622276 Cunanan et al. Nov 2009 B2
7628803 Pavcnik et al. Dec 2009 B2
7632298 Hijlkema et al. Dec 2009 B2
7641687 Chinn et al. Jan 2010 B2
7674282 Wu et al. Mar 2010 B2
7712606 Salahieh et al. May 2010 B2
7722638 Deyette et al. May 2010 B2
7722662 Steinke et al. May 2010 B2
7722666 Lafontaine May 2010 B2
7731742 Schlick et al. Jun 2010 B2
7736388 Goldfarb et al. Jun 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7758625 Wu et al. Jul 2010 B2
7780725 Haug et al. Aug 2010 B2
7799065 Pappas Sep 2010 B2
7803185 Gabbay Sep 2010 B2
7824442 Salahieh et al. Nov 2010 B2
7824443 Salahieh et al. Nov 2010 B2
7833262 McGuckin et al. Nov 2010 B2
7846204 Letac et al. Dec 2010 B2
7857845 Stacchino et al. Dec 2010 B2
7892292 Stack et al. Feb 2011 B2
7918880 Austin Apr 2011 B2
7938851 Olson et al. May 2011 B2
7959666 Salahieh et al. Jun 2011 B2
7959672 Salahieh et al. Jun 2011 B2
7988724 Salahieh et al. Aug 2011 B2
8048153 Salahieh et al. Nov 2011 B2
8052749 Salahieh et al. Nov 2011 B2
8136659 Salahieh et al. Mar 2012 B2
8157853 Laske et al. Apr 2012 B2
8172896 McNamara et al. May 2012 B2
8182528 Salahieh et al. May 2012 B2
8192351 Fishier et al. Jun 2012 B2
8226710 Nguyen et al. Jul 2012 B2
8231670 Salahieh et al. Jul 2012 B2
8236049 Rowe et al. Aug 2012 B2
8246678 Salahieh et al. Aug 2012 B2
8252051 Chau et al. Aug 2012 B2
8252052 Salahieh et al. Aug 2012 B2
8287584 Salahieh et al. Oct 2012 B2
8308798 Pintor et al. Nov 2012 B2
8317858 Straubinger et al. Nov 2012 B2
8323335 Rowe et al. Dec 2012 B2
8328868 Paul et al. Dec 2012 B2
8343213 Salahieh et al. Jan 2013 B2
8376865 Forster et al. Feb 2013 B2
8377117 Keidar et al. Feb 2013 B2
8398708 Meiri et al. Mar 2013 B2
8403983 Quadri et al. Mar 2013 B2
8414644 Quadri et al. Apr 2013 B2
8579962 Salahieh et al. Nov 2013 B2
8603160 Salahieh et al. Dec 2013 B2
8617236 Paul et al. Dec 2013 B2
8623074 Ryan Jan 2014 B2
8623076 Salahieh et al. Jan 2014 B2
8623078 Salahieh et al. Jan 2014 B2
8647381 Essinger et al. Feb 2014 B2
8668733 Haug et al. Mar 2014 B2
8696743 Holecek et al. Apr 2014 B2
8828078 Salahieh et al. Sep 2014 B2
8840662 Salahieh et al. Sep 2014 B2
8840663 Salahieh et al. Sep 2014 B2
8858620 Salahieh et al. Oct 2014 B2
8894703 Salahieh et al. Nov 2014 B2
8951299 Paul et al. Feb 2015 B2
8992608 Haug et al. Mar 2015 B2
9005273 Salahieh et al. Apr 2015 B2
9011521 Haug et al. Apr 2015 B2
9168131 Yohanan et al. Oct 2015 B2
9216082 Von Segesser et al. Dec 2015 B2
9333075 Biadillah et al. May 2016 B2
9414915 Lombardi et al. Aug 2016 B2
20010002445 Vesely May 2001 A1
20010007956 Letac et al. Jul 2001 A1
20010010017 Letac et al. Jul 2001 A1
20010021872 Bailey et al. Sep 2001 A1
20010025196 Chinn et al. Sep 2001 A1
20010027338 Greenberg Oct 2001 A1
20010032013 Marton Oct 2001 A1
20010039450 Pavcnik et al. Nov 2001 A1
20010041928 Pavcnik et al. Nov 2001 A1
20010041930 Globerman et al. Nov 2001 A1
20010044634 Michael et al. Nov 2001 A1
20010044652 Moore Nov 2001 A1
20010044656 Williamson et al. Nov 2001 A1
20020002396 Fulkerson Jan 2002 A1
20020010489 Grayzel et al. Jan 2002 A1
20020026233 Shaknovich Feb 2002 A1
20020029014 Jayaraman Mar 2002 A1
20020029981 Nigam Mar 2002 A1
20020032480 Spence et al. Mar 2002 A1
20020032481 Gabbay Mar 2002 A1
20020042651 Liddicoat et al. Apr 2002 A1
20020052651 Myers et al. May 2002 A1
20020055767 Forde et al. May 2002 A1
20020055769 Wang May 2002 A1
20020055774 Liddicoat May 2002 A1
20020058987 Butaric et al. May 2002 A1
20020058995 Stevens May 2002 A1
20020077696 Zadno-Azizi et al. Jun 2002 A1
20020082609 Green Jun 2002 A1
20020095173 Mazzocchi et al. Jul 2002 A1
20020095209 Zadno-Azizi et al. Jul 2002 A1
20020111674 Chouinard et al. Aug 2002 A1
20020120328 Pathak et al. Aug 2002 A1
20020123802 Snyders Sep 2002 A1
20020138138 Yang Sep 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020156522 Ivancev et al. Oct 2002 A1
20020161390 Mouw Oct 2002 A1
20020161392 Dubrul Oct 2002 A1
20020161394 Macoviak et al. Oct 2002 A1
20020165576 Boyle et al. Nov 2002 A1
20020177766 Mogul Nov 2002 A1
20020183781 Casey et al. Dec 2002 A1
20020188341 Elliott Dec 2002 A1
20020188344 Bolea et al. Dec 2002 A1
20020193871 Beyersdorf et al. Dec 2002 A1
20030014104 Cribier Jan 2003 A1
20030023303 Palmaz et al. Jan 2003 A1
20030028247 Cali Feb 2003 A1
20030036791 Philipp et al. Feb 2003 A1
20030040736 Stevens et al. Feb 2003 A1
20030040771 Hyodoh et al. Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030040791 Oktay Feb 2003 A1
20030040792 Gabbay Feb 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030055495 Pease et al. Mar 2003 A1
20030057156 Peterson et al. Mar 2003 A1
20030060844 Borillo et al. Mar 2003 A1
20030069492 Abrams et al. Apr 2003 A1
20030069646 Stinson Apr 2003 A1
20030070944 Nigam Apr 2003 A1
20030074058 Sherry Apr 2003 A1
20030093145 Lawrence-Brown et al. May 2003 A1
20030100918 Duane May 2003 A1
20030100919 Hopkins et al. May 2003 A1
20030109924 Cribier Jun 2003 A1
20030109930 Bluni et al. Jun 2003 A1
20030114912 Sequin et al. Jun 2003 A1
20030114913 Spenser et al. Jun 2003 A1
20030125795 Pavcnik et al. Jul 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030135257 Taheri Jul 2003 A1
20030144732 Cosgrove et al. Jul 2003 A1
20030149475 Hyodoh et al. Aug 2003 A1
20030149476 Damm et al. Aug 2003 A1
20030149478 Figulla et al. Aug 2003 A1
20030153974 Spenser et al. Aug 2003 A1
20030165352 Ibrahim et al. Sep 2003 A1
20030171803 Shimon Sep 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030181850 Diamond et al. Sep 2003 A1
20030187495 Cully et al. Oct 2003 A1
20030191516 Weldon et al. Oct 2003 A1
20030195609 Berenstein et al. Oct 2003 A1
20030199759 Richard Oct 2003 A1
20030199913 Dubrul et al. Oct 2003 A1
20030199971 Tower et al. Oct 2003 A1
20030199972 Zadno-Azizi et al. Oct 2003 A1
20030204249 Letort Oct 2003 A1
20030208224 Broome Nov 2003 A1
20030212429 Keegan et al. Nov 2003 A1
20030212452 Zadno-Azizi et al. Nov 2003 A1
20030212454 Scott et al. Nov 2003 A1
20030216774 Larson Nov 2003 A1
20030225445 Derus et al. Dec 2003 A1
20030229390 Ashton et al. Dec 2003 A1
20030233117 Adams et al. Dec 2003 A1
20030236567 Elliot Dec 2003 A1
20040019374 Hojeibane et al. Jan 2004 A1
20040033364 Spiridigliozzi et al. Feb 2004 A1
20040034411 Quijano et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040049224 Buehlmann et al. Mar 2004 A1
20040049226 Keegan et al. Mar 2004 A1
20040049262 Obermiller et al. Mar 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040059409 Stenzel Mar 2004 A1
20040073198 Gilson et al. Apr 2004 A1
20040082904 Houde et al. Apr 2004 A1
20040082967 Broome et al. Apr 2004 A1
20040082989 Cook et al. Apr 2004 A1
20040087982 Eskuri May 2004 A1
20040088045 Cox May 2004 A1
20040093016 Root et al. May 2004 A1
20040093060 Seguin et al. May 2004 A1
20040097788 Mourlas et al. May 2004 A1
20040098022 Barone May 2004 A1
20040098098 McGuckin et al. May 2004 A1
20040098099 McCullagh et al. May 2004 A1
20040098112 DiMatteo et al. May 2004 A1
20040107004 Levine et al. Jun 2004 A1
20040111096 Tu et al. Jun 2004 A1
20040116951 Rosengart Jun 2004 A1
20040116999 Ledergerber Jun 2004 A1
20040117004 Osborne et al. Jun 2004 A1
20040117009 Cali et al. Jun 2004 A1
20040122468 Yodfat et al. Jun 2004 A1
20040122516 Fogarty et al. Jun 2004 A1
20040127936 Salahieh et al. Jul 2004 A1
20040127979 Wilson et al. Jul 2004 A1
20040133274 Webler et al. Jul 2004 A1
20040138694 Tran et al. Jul 2004 A1
20040138742 Myers et al. Jul 2004 A1
20040138743 Myers et al. Jul 2004 A1
20040148018 Carpentier et al. Jul 2004 A1
20040148021 Cartledge et al. Jul 2004 A1
20040153094 Dunfee et al. Aug 2004 A1
20040158277 Lowe et al. Aug 2004 A1
20040167565 Beulke et al. Aug 2004 A1
20040167620 Ortiz et al. Aug 2004 A1
20040181140 Falwell et al. Sep 2004 A1
20040186558 Pavcnik et al. Sep 2004 A1
20040186563 Lobbi Sep 2004 A1
20040193261 Berreklouw Sep 2004 A1
20040197695 Aono Oct 2004 A1
20040199245 Lauterjung Oct 2004 A1
20040204755 Robin Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040210306 Quijano et al. Oct 2004 A1
20040210307 Khairkhahan Oct 2004 A1
20040215331 Chew et al. Oct 2004 A1
20040215333 Duran et al. Oct 2004 A1
20040215339 Drasler et al. Oct 2004 A1
20040220655 Swanson et al. Nov 2004 A1
20040225321 Krolik et al. Nov 2004 A1
20040225353 McGuckin et al. Nov 2004 A1
20040225354 Allen et al. Nov 2004 A1
20040225355 Stevens Nov 2004 A1
20040243221 Fawzi et al. Dec 2004 A1
20040254636 Flagle et al. Dec 2004 A1
20040260390 Sarac et al. Dec 2004 A1
20050010287 Macoviak et al. Jan 2005 A1
20050021136 Xie et al. Jan 2005 A1
20050033398 Seguin Feb 2005 A1
20050033402 Cully et al. Feb 2005 A1
20050043711 Corcoran et al. Feb 2005 A1
20050043757 Arad et al. Feb 2005 A1
20050043790 Seguin Feb 2005 A1
20050049692 Numamoto et al. Mar 2005 A1
20050049696 Siess et al. Mar 2005 A1
20050055088 Liddicoat et al. Mar 2005 A1
20050060016 Wu et al. Mar 2005 A1
20050060029 Le et al. Mar 2005 A1
20050065594 DiMatteo et al. Mar 2005 A1
20050075584 Cali Apr 2005 A1
20050075662 Pedersen et al. Apr 2005 A1
20050075712 Biancucci et al. Apr 2005 A1
20050075717 Nguyen et al. Apr 2005 A1
20050075719 Bergheim Apr 2005 A1
20050075724 Svanidze et al. Apr 2005 A1
20050075730 Myers et al. Apr 2005 A1
20050075731 Artof et al. Apr 2005 A1
20050085841 Eversull et al. Apr 2005 A1
20050085842 Eversull et al. Apr 2005 A1
20050085843 Opolski et al. Apr 2005 A1
20050085890 Rasmussen et al. Apr 2005 A1
20050090846 Pedersen et al. Apr 2005 A1
20050090890 Wu et al. Apr 2005 A1
20050096692 Linder et al. May 2005 A1
20050096734 Majercak et al. May 2005 A1
20050096735 Hojeibane et al. May 2005 A1
20050096736 Osse et al. May 2005 A1
20050096738 Cali et al. May 2005 A1
20050100580 Osborne et al. May 2005 A1
20050107822 WasDyke May 2005 A1
20050113910 Paniagua et al. May 2005 A1
20050131438 Cohn Jun 2005 A1
20050137683 Hezi-Yamit et al. Jun 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137687 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137689 Salahieh et al. Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137692 Haug et al. Jun 2005 A1
20050137693 Haug et al. Jun 2005 A1
20050137694 Haug et al. Jun 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137696 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050137698 Salahieh et al. Jun 2005 A1
20050137699 Salahieh et al. Jun 2005 A1
20050137701 Salahieh et al. Jun 2005 A1
20050137702 Haug et al. Jun 2005 A1
20050138689 Aukerman Jun 2005 A1
20050143807 Pavcnik et al. Jun 2005 A1
20050143809 Salahieh et al. Jun 2005 A1
20050149159 Andreas et al. Jul 2005 A1
20050165352 Henry et al. Jul 2005 A1
20050165477 Anduiza et al. Jul 2005 A1
20050165479 Drews et al. Jul 2005 A1
20050182486 Gabbay Aug 2005 A1
20050197694 Pai et al. Sep 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050203549 Realyvasquez Sep 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050203615 Forster et al. Sep 2005 A1
20050203616 Cribier Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050203618 Sharkawy et al. Sep 2005 A1
20050203818 Rotman et al. Sep 2005 A9
20050209580 Freyman Sep 2005 A1
20050228472 Case et al. Oct 2005 A1
20050228495 Macoviak Oct 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050240262 White Oct 2005 A1
20050251250 Verhoeven et al. Nov 2005 A1
20050251251 Cribier Nov 2005 A1
20050261759 Lambrecht et al. Nov 2005 A1
20050267560 Bates Dec 2005 A1
20050283231 Haug et al. Dec 2005 A1
20050283962 Boudjemline Dec 2005 A1
20060004439 Spenser et al. Jan 2006 A1
20060004442 Spenser et al. Jan 2006 A1
20060015168 Gunderson Jan 2006 A1
20060025857 Bergheim et al. Feb 2006 A1
20060058872 Salahieh et al. Mar 2006 A1
20060149360 Schwammenthal et al. Jul 2006 A1
20060155312 Levine et al. Jul 2006 A1
20060161249 Realyvasquez et al. Jul 2006 A1
20060173524 Salahieh et al. Aug 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060253191 Salahieh et al. Nov 2006 A1
20060259134 Schwammenthal et al. Nov 2006 A1
20060271166 Thill et al. Nov 2006 A1
20060287668 Fawzi et al. Dec 2006 A1
20060287717 Rowe et al. Dec 2006 A1
20070010876 Salahieh et al. Jan 2007 A1
20070010877 Salahieh et al. Jan 2007 A1
20070016286 Herrmann et al. Jan 2007 A1
20070055340 Pryor Mar 2007 A1
20070061008 Salahieh et al. Mar 2007 A1
20070112355 Salahieh et al. May 2007 A1
20070118214 Salahieh et al. May 2007 A1
20070162107 Haug et al. Jul 2007 A1
20070173918 Dreher et al. Jul 2007 A1
20070203503 Salahieh et al. Aug 2007 A1
20070244552 Salahieh et al. Oct 2007 A1
20070288089 Gurskis et al. Dec 2007 A1
20080009940 Cribier Jan 2008 A1
20080033541 Gelbart et al. Feb 2008 A1
20080071363 Tuval et al. Mar 2008 A1
20080082165 Wilson et al. Apr 2008 A1
20080125859 Salahieh et al. May 2008 A1
20080188928 Salahieh et al. Aug 2008 A1
20080208328 Antocci et al. Aug 2008 A1
20080208332 Lamphere et al. Aug 2008 A1
20080221672 Lamphere et al. Sep 2008 A1
20080234814 Salahieh et al. Sep 2008 A1
20080255661 Straubinger et al. Oct 2008 A1
20080269878 Iobbi Oct 2008 A1
20080288054 Pulnev et al. Nov 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090030512 Thielen et al. Jan 2009 A1
20090054969 Salahieh et al. Feb 2009 A1
20090076598 Salahieh et al. Mar 2009 A1
20090093877 Keidar et al. Apr 2009 A1
20090171456 Kveen et al. Jul 2009 A1
20090216312 Straubinger et al. Aug 2009 A1
20090222076 Figulla et al. Sep 2009 A1
20090264759 Byrd Oct 2009 A1
20090264997 Salahieh et al. Oct 2009 A1
20090299462 Fawzi et al. Dec 2009 A1
20100004730 Benjamin Jan 2010 A1
20100036479 Hill et al. Feb 2010 A1
20100049313 Alon et al. Feb 2010 A1
20100082089 Quadri et al. Apr 2010 A1
20100094399 Dorn et al. Apr 2010 A1
20100121434 Paul et al. May 2010 A1
20100161045 Righini Jun 2010 A1
20100185275 Richter et al. Jul 2010 A1
20100191320 Straubinger et al. Jul 2010 A1
20100191326 Alkhatib Jul 2010 A1
20100219092 Salahieh et al. Sep 2010 A1
20100249908 Chau et al. Sep 2010 A1
20100280495 Paul et al. Nov 2010 A1
20100298931 Quadri et al. Nov 2010 A1
20110257735 Salahieh et al. Oct 2011 A1
20110264196 Savage et al. Oct 2011 A1
20110276129 Salahieh et al. Nov 2011 A1
20110288634 Tuval et al. Nov 2011 A1
20110295363 Girard et al. Dec 2011 A1
20110307049 Kao Dec 2011 A1
20120016469 Salahieh et al. Jan 2012 A1
20120016471 Salahieh et al. Jan 2012 A1
20120022642 Haug et al. Jan 2012 A1
20120029627 Salahieh et al. Feb 2012 A1
20120041549 Salahieh et al. Feb 2012 A1
20120041550 Salahieh et al. Feb 2012 A1
20120046740 Paul et al. Feb 2012 A1
20120053683 Salahieh et al. Mar 2012 A1
20120089224 Haug et al. Apr 2012 A1
20120132547 Salahieh et al. May 2012 A1
20120179244 Schankereli et al. Jul 2012 A1
20120197379 Laske et al. Aug 2012 A1
20120271398 Essinger et al. Oct 2012 A1
20120303113 Benichou et al. Nov 2012 A1
20120303116 Gorman et al. Nov 2012 A1
20120330409 Haug et al. Dec 2012 A1
20130013057 Salahieh et al. Jan 2013 A1
20130018457 Gregg et al. Jan 2013 A1
20130030519 Tran et al. Jan 2013 A1
20130030520 Lee et al. Jan 2013 A1
20130079867 Hoffman et al. Mar 2013 A1
20130079869 Straubinger et al. Mar 2013 A1
20130096664 Goetz et al. Apr 2013 A1
20130123796 Sutton et al. May 2013 A1
20130138207 Quadri et al. May 2013 A1
20130158656 Sutton et al. Jun 2013 A1
20130184813 Quadri et al. Jul 2013 A1
20130190865 Anderson Jul 2013 A1
20130231736 Essinger et al. Sep 2013 A1
20130304199 Sutton et al. Nov 2013 A1
20140018911 Zhou et al. Jan 2014 A1
20140039614 Delaloye et al. Feb 2014 A1
20140094904 Salahieh et al. Apr 2014 A1
20140114405 Paul et al. Apr 2014 A1
20140114406 Salahieh et al. Apr 2014 A1
20140121766 Salahieh et al. May 2014 A1
20140135912 Salahieh et al. May 2014 A1
20140200649 Essinger et al. Jul 2014 A1
20140243967 Salahieh et al. Aug 2014 A1
20140330219 Quint Nov 2014 A1
20150012085 Salahieh et al. Jan 2015 A1
20150018938 Von Segesser et al. Jan 2015 A1
20150073540 Salahieh et al. Mar 2015 A1
20150073541 Salahieh et al. Mar 2015 A1
20150127094 Salahieh et al. May 2015 A1
20150245934 Lombardi et al. Sep 2015 A1
20150297381 Essinger et al. Oct 2015 A1
20150305863 Gray Oct 2015 A1
20150366665 Lombardi et al. Dec 2015 A1
20160038281 Delaloye et al. Feb 2016 A1
20160045307 Yohanan et al. Feb 2016 A1
20160058434 Delaloye et al. Mar 2016 A1
20160193047 Delaloye et al. Jul 2016 A1
20160199184 Ma et al. Jul 2016 A1
20160228249 Mantanus et al. Aug 2016 A1
20160262884 Lombardi et al. Sep 2016 A1
20170035568 Lombardi et al. Feb 2017 A1
20170224486 Delaloye et al. Aug 2017 A1
20180161064 Fitterer et al. Jun 2018 A1
Foreign Referenced Citations (178)
Number Date Country
2002329324 Jul 2007 AU
1338951 Mar 2002 CN
19532846 Mar 1997 DE
19546692 Jun 1997 DE
19857887 Jul 2000 DE
19907646 Aug 2000 DE
10049812 Apr 2002 DE
10049813 Apr 2002 DE
10049814 Apr 2002 DE
10049815 Apr 2002 DE
0103546 May 1988 EP
0144167 Nov 1989 EP
579523 Jan 1994 EP
0409929 Apr 1997 EP
0850607 Jul 1998 EP
0597967 Dec 1999 EP
1000590 May 2000 EP
1057459 Dec 2000 EP
1057460 Dec 2000 EP
1078610 Feb 2001 EP
1088529 Apr 2001 EP
0937439 Sep 2003 EP
1340473 Sep 2003 EP
1356793 Mar 2004 EP
1042045 May 2004 EP
0819013 Jun 2004 EP
1430853 Jun 2004 EP
1435879 Jul 2004 EP
1439800 Jul 2004 EP
1469797 Oct 2004 EP
1472996 Nov 2004 EP
1229864 Apr 2005 EP
1059894 Jul 2005 EP
1551274 Jul 2005 EP
1551336 Jul 2005 EP
1562515 Aug 2005 EP
1570809 Sep 2005 EP
1576937 Sep 2005 EP
1582178 Oct 2005 EP
1582179 Oct 2005 EP
1589902 Nov 2005 EP
1600121 Nov 2005 EP
1156757 Dec 2005 EP
1616531 Jan 2006 EP
1690515 Aug 2006 EP
1605871 Jul 2008 EP
2047824 May 2012 EP
2749254 Jun 2015 EP
2926766 Oct 2015 EP
2788217 Jul 2000 FR
2056023 Mar 1981 GB
2398245 Aug 2004 GB
1271508 Nov 1986 SU
1371700 Feb 1988 SU
9117720 Nov 1991 WO
9217118 Oct 1992 WO
9301768 Feb 1993 WO
9315693 Aug 1993 WO
9504556 Feb 1995 WO
9529640 Nov 1995 WO
9614032 May 1996 WO
9624306 Aug 1996 WO
9640012 Dec 1996 WO
9748350 Dec 1997 WO
9829057 Jul 1998 WO
9836790 Aug 1998 WO
9850103 Nov 1998 WO
9855047 Dec 1998 WO
9857599 Dec 1998 WO
9933414 Jul 1999 WO
9940964 Aug 1999 WO
9944542 Sep 1999 WO
9947075 Sep 1999 WO
9951165 Oct 1999 WO
0009059 Feb 2000 WO
2000009059 Feb 2000 WO
0041652 Jul 2000 WO
0044308 Aug 2000 WO
0044311 Aug 2000 WO
0044313 Aug 2000 WO
0045874 Aug 2000 WO
0047139 Aug 2000 WO
0049970 Aug 2000 WO
0067661 Nov 2000 WO
0105331 Jan 2001 WO
0106959 Feb 2001 WO
0108596 Feb 2001 WO
0110320 Feb 2001 WO
0110343 Feb 2001 WO
0135870 May 2001 WO
0149213 Jul 2001 WO
0154625 Aug 2001 WO
0162189 Aug 2001 WO
2001054625 Aug 2001 WO
0164137 Sep 2001 WO
0176510 Oct 2001 WO
0197715 Dec 2001 WO
0236048 May 2002 WO
0241789 May 2002 WO
0243620 Jun 2002 WO
0247575 Jun 2002 WO
02056955 Jul 2002 WO
02069842 Aug 2002 WO
02069842 Sep 2002 WO
02100297 Dec 2002 WO
03003943 Jan 2003 WO
03003949 Jan 2003 WO
03011195 Feb 2003 WO
03015851 Feb 2003 WO
03028592 Apr 2003 WO
03030776 Apr 2003 WO
03032869 Apr 2003 WO
03037222 May 2003 WO
03037227 May 2003 WO
03047468 Jun 2003 WO
03047648 Jun 2003 WO
03088873 Oct 2003 WO
03094793 Nov 2003 WO
03094797 Nov 2003 WO
03096932 Nov 2003 WO
2004006803 Jan 2004 WO
2004006804 Jan 2004 WO
2004014256 Feb 2004 WO
2004019817 Mar 2004 WO
2004021922 Mar 2004 WO
2004023980 Mar 2004 WO
2004019811 Apr 2004 WO
2004026117 Apr 2004 WO
2004041126 May 2004 WO
2004043293 May 2004 WO
2004047681 Jun 2004 WO
2004058106 Aug 2004 WO
2004066876 Aug 2004 WO
2004082536 Sep 2004 WO
2004089250 Oct 2004 WO
2004089253 Oct 2004 WO
2004093728 Nov 2004 WO
2004105651 Dec 2004 WO
2005002466 Jan 2005 WO
2005004753 Jan 2005 WO
2005009285 Feb 2005 WO
2005011534 Feb 2005 WO
2005011535 Feb 2005 WO
2005023155 Mar 2005 WO
2005027790 Mar 2005 WO
2005046528 May 2005 WO
2005046529 May 2005 WO
2005048883 Jun 2005 WO
2005065585 Jul 2005 WO
2005084595 Sep 2005 WO
2005087140 Sep 2005 WO
2005096993 Oct 2005 WO
2006005015 Jan 2006 WO
2006009690 Jan 2006 WO
2006027499 Mar 2006 WO
2005062980 May 2006 WO
2006093795 Sep 2006 WO
2006138391 Dec 2006 WO
2007009117 Jan 2007 WO
2007033093 Mar 2007 WO
2007035471 Mar 2007 WO
2005102015 Apr 2007 WO
2007044285 Apr 2007 WO
2007058847 May 2007 WO
2007092354 Aug 2007 WO
2007097983 Aug 2007 WO
2007053243 Sep 2007 WO
2008028569 Mar 2008 WO
2008035337 Mar 2008 WO
2010042950 Apr 2010 WO
2010098857 Sep 2010 WO
2012116368 Aug 2012 WO
2012162228 Nov 2012 WO
2013009975 Jan 2013 WO
2013028387 Feb 2013 WO
2013074671 May 2013 WO
2013096545 Jun 2013 WO
2016126511 Aug 2016 WO
Non-Patent Literature Citations (108)
Entry
US 8,062,356 B2, 11/2011, Salahieh et al. (withdrawn)
US 8,062,357 B2, 11/2011, Salahieh et al. (withdrawn)
US 8,075,614 B2, 12/2011, Salahieh et al. (withdrawn)
US 8,133,271 B2, 03/2012, Salahieh et al. (withdrawn)
US 8,211,170 B2, 07/2012, Paul et al. (withdrawn)
Carpentier-Edwards PERIMOUNT Bioprosthesis (2003).
International Search Report and Written Opinion dated Oct. 22, 2018 for International Application No. PCT/US2018/044318.
Cribier et al., “Percutaneous Transluminal Valvuloplasty of Acquired Aortic Stenosis in Elderly Patients: An Alternative to Valve Replacement?” The Lancet, 63-7 (Jan. 11, 1986).
Supplemental Search Report from EP Patent Office, EP Application No. 04813777.2, dated Aug. 19, 2011.
Laborde et al., “Percutaneous Implantation of the Corevalve Aortic Valve Prosthesis for Patients Presenting High Risk for Surgical Valve Replacement.” EuroIntervention: 472-474, Feb. 2006.
“A Matter of Size.” Triennial Review of the National Nanotechnology Initiative, The National Academies Press, Washington DC, v-13, http://www.nap.edu/catalog/11752/a-matter-of-size-triennial-review-of-the-national-nanotechnology, 2006.
“Heart Valve Materials—Bovine (cow).” Equine & Porcine Pericardium, Maverick Biosciences Pty. Lt, http://maverickbio.com/biological-medical-device-materials.php?htm. 2009.
“Pericardial Heart Valves.” Edwards Lifesciences, Cardiovascular Surgery FAQ, http://www.edwards.com/products/cardiovascularsurgeryfaq.htm, Nov. 14, 2010.
Allen et al., “What are the characteristics of the ideal endovascular graft for abdominal aortic aneurysm exclusion?” J. Endovasc. Surg., 4(2):195-202 (May 1997).
Andersen et al. “Transluminal catheter implantation of a new expandable artificial cardiac valve (the stent—valve) in the aorta and the beating heart of closed chest pigs (Abstract).” Eur. Heart J., 11 (SuppL): 224a (1990).
Andersen et al., “Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs.” Euro. Heart J., 13:704-708, May 1992.
Atwood et al., “Insertion of Heart Valves by Catheterization.” Project Supervised by Prof. S. Muftu of Northeastern University 2001-2002: 36-40, May 30, 2002.
Atwood et al., “Insertion of Heart Valves by Catheterization.” The Capstone Design Course Report. MIME 1501-1502 Technical Design Report. Northeastern University, pp. 1-93, Nov. 5, 2007.
Bailey, “Percutaneous Expandable Prosthetic Valves, Textbook of Interventional Cardiology.” vol. 2, 2d ed. Eric J. Topol, W.B. Saunders Co. (1994).
Blum et al., “Endoluminal Stent-Grafts for Intrarenal Abdominal Aortic Aneurysms.” New Engl. J. Med., 336:13-20 (1997).
Bodnar et al., “Replacement Cardiac Valves R Chapter 13: Extinct Cardiac Valve Prostheses.” Pergamon Publishing Corporation New York, 307-322, 1991.
Bonhoeffer et al., “Percutaneous Insertion of the Pulmonary Valve.” J. Am. Coll. Cardiol., 39:1664-9 (2002).
Bonhoeffer et al., “Transcatheter Implantation of a Bovine Valve in Pulmonary Position: A Lamb Study.” Circulation, 102: 813-16 (2000).
Bonhoeffer, et al., “Percutaneous replacement of pulmonary valve in a right ventricle to pulmonary-artery prosthetic conduit with valve dysfunction.” The Lancet, vol. 356, 1403-05 (Oct. 21, 2000).
Boudjemline et al., “Percutaneous Implantation of a Biological Valve in the Aorta to Treat Aortic Valve Insufficiency—A Sheep Study.” Med Sci. Monit., vol. 8, No. 4: BR113-116, Apr. 12, 2002.
Boudjemline et al., “Percutaneous Implantation of a Valve in the Descending Aorta in Lambs.” Euro. Heart J., 23: 1045-1049, Jul. 2002.
Boudjemline et al., “Percutaneous Pulmonary Valve Replacement in a Large Right Ventricular Outflow Tract: An Experimental Study.” Journal of the American College of Cardiology, vol. 43(6): 1082-1087, Mar. 17, 2004.
Boudjemline et al., “Percutaneous Valve Insertion: A New Approach?” J. of Thoracic and Cardio. Surg, 125(3): 741-743, Mar. 2003.
Boudjemline et al., “Steps Toward Percutaneous Aortic Valve Replacement.” Circulation, 105: 775-778, Feb. 12, 2002.
Couper, “Surgical Aspects of Prosthetic Valve Selection,” Overview of Cardiac Surgery for the Cardiologist, Springer-Verlag New York, Inc., 131-145 (1994).
Cribier et al., “Early Experience with Percutaneous Transcatheter Implantation of Heart Valve Prosthesis for the Treatment of End-Stage Inoperable Patients with Calcific Aortic Stenosis.” J. of Am. Coll. of Cardio, 43(4): 698-703, Feb. 18, 2004.
Cribier et al., “Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis First Human Case.” Percutaneous Valve Technologies, Inc., 16 pages, Apr. 16, 2002.
Cribier et al., “Percutaneous Transcatheter Implementation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description.” Circulation, 106: 3006-3008, Dec. 10, 2002.
Cribier et al., “Trans-Cathether Implantation of Balloon-Expandable Prosthetic Heart Valves: Early Results in an Animal Model.” Circulation [suppl. II] 104(17) II-552 (Oct. 23, 2001).
Cunanan et al., “Tissue Characterization and Calcification Potential of Commercial Bioprosthetic Heart Valves.” Ann. Thorac. Surg., S417-421, May 15, 2001.
Cunliffe et al., “Glutaraldehyde Inactivation of Exotic Animal Viruses in Swine Heart Tissue.” Applied and Environmental Microbiology, Greenport, New York, 37(5): 1044-1046, May 1979.
Dake et al., “Transluminal Placement of Endovascular Stent-Grafts for the Treatment of Descending Thoracic Aortic Aneurysms.” New Engl. J of Med., 331(26):1729-34 (1994).
Dalby et al., “Non-Surgical Aortic Valve Replacement” Br. J. Cardiol., 10:450-2 (2003).
Dhasmana, et al., “Factors Associated With Periprosthetic Leakage Following Primary Mitral Valve Replacement: With Special Consideration of Suture Technique.” Annals of Thorac. Surg. 35(2), 170-8 (Feb. 1983).
Diethrich, AAA Stent Grafts: Current Developments, J. Invasive Cardiol. 13(5) (2001).
Dolmatch et al., Stent Grafts: Current Clinical Practice (2000)—EVT Endograft and Talent Endoprosthesis.
Dotter, “Transluminally-Placed Coilspring Endarterial Tube Grafts,” Investigative Radiology, pp. 329-332 (1969).
Emery et al., “Replacement of the Aortic Valve in Patients Under 50 Years of Age: Long-Term Follow-Up of the St. Jude Medical Prosthesis.” Ann. Thorac. Surg., 75:1815-9 (2003).
EP Search Report for EP Application No. 06824992.9, dated Aug. 10, 2011.
Examiner's First Report on AU Patent Application No. 2011202667, dated May 17, 2012.
Ferrari et al., “Percutaneous Transvascular Aortic Valve Replacement with Self-Expanding Stent-Valve Device.” Poster from the presentation given at SMIT 2000, 12th International Conference Sep. 5, 2000.
Greenberg, “Abdominal Aortic Endografting: Fixation and Sealing.” J. Am. Coll. Surg. 194:1:S79-S87 (2002).
Grossi, “Impact of Minimally Invasive Valvular Heart Surgery: A Case-Control Study.” Ann. Thorac. Surg., 71:807-10 (2001).
Helmus, “Mechanical and Bioprosthetic Heart Valves in Biomaterials for Artificial Organs.” Woodhead Publishing Limited: 114-162, 2011.
Hijazi, “Transcatheter Valve Replacement: A New Era of Percutaneous Cardiac Intervention Begins.” J. of Am. College of Cardio., 43(6): 1088-1089, Mar. 17, 2004.
Hourihan et al., “Transcatheter Umbrella Closure of Valvular and Paravalvular Leaks.” JACC, Boston, Massachusetts, 20(6): 1371-1377, Nov. 15, 1992.
Huber et al., “Do Valved Stents Compromise Coronary Flow?” European Journal of Cardio-thoracic Surgery, vol. 25: 754-759, Jan. 23, 2004.
Ing, “Stents: What's Available to the Pediatric Interventional Cardiologist?” Catheterization and Cardiovascular Interventions 57:274-386 (2002).
Ionescu, et al., “Prevalence and Clinical Significance of Incidental Paraprosthetic Valvar Regurgitation: A prospective study using transesophageal echocardiography.” Heart, 89:1316-21 (2003).
Kaiser, et al., “Surgery for Left Ventricle Outflow Obstruction: Aortic Valve Replacement and Myomectomy,” Overview of Cardiac Surgery for the Cardiologist. Springer-Verlag New York, Inc., 40-45 (1994).
Kato et al., “Traumatic Thoracic Aortic Aneurysm: Treatment with Endovascular Stent-Grafts.” Radiol., 205: 657-662 (1997).
Khonsari et al., “Cardiac Surgery: Safeguards and Pitfalls in Operative Technique.” 3d ed., 45-74 (2003).
Knudsen et al., “Catheter-implanted prosthetic heart valves.” Int'l J. of Art. Organs, 16(5): 253-262, May 1993.
Kort et al., “Minimally Invasive Aortic Valve Replacement: Echocardiographic and Clinical Results.” Am Heart J., 142(3): 476-481, Sep. 2001.
Lawrence et al., “Percutaneous Endovascular Graft: Experimental Evaluation,” Radiology, 163(2): 357-60 (May 1987).
Levi et al., “Future of Interventional Cardiology in Pediactrics.” Current Opinion in Cardiol., 18:79-90 (2003).
Levy, “Mycobacterium chelonei Infection of Porcine Heart Valves.” The New England Journal of Medicine, Washington DC, 297(12), Sep. 22, 1977.
Love et al., The Autogenous Tissue Heart Valve: Current Status. Journal of Cardiac Surgery, 6(4): 499-507, Mar. 1991.
Lutter et al., “Percutaneous Aortic Valve Replacement: An Experimental Study. I. Studies on Implantation.” J. of Thoracic and Cardio. Surg., 123(4): 768-776, Apr. 2002.
Magovern et al., “Twenty-five-Year Review of the Magovern-Cromie Sutureless Aortic Valve.” Ann. Thorac. Surg., 48: S33-4 (1989).
Maraj et al., Evaluation of Hemolysis in Patients with Prosthetic Heart Valves, Clin. Cardiol. 21, 387-392 (1998).
Mckay et al., “The Mansfield Scientific Aortic Valvuloplasty Registry: Overview of Acute Hemodynamic Results and Procedural Complications.” J. Am. Coll. Cardiol. 17(2): 485-91 (Feb. 1991).
Mirich et al., “Percutaneously Placed Endovascular Grafts for Aortic Aneurysms: Feasibility Study.” Radiology, 170: 1033-1037(1989).
Moazami et al., “Transluminal Aortic Valve Placement: A Feasibility Study With a Newly Designed Collapsiable Aortic Valve,” ASAIO J vol. 42:5, pp. M383-85 (Sep./Oct. 1996).
Moulopoulos et al., “Catheter-Mounted Aortic Valves.” Annals of Thoracic Surg., 11 (5): 423-430, May 1971.
Paniagua et al., “Heart Watch.” Texas Heart Institute. Edition: 8 pages, Spring, 2004.
Paniagua et al., “Percutaneous Heart Valve in the Chronic in Vitro Testing Model.” Circulation, 106: e51-e52, Sep. 17, 2002.
Parodi et al., “Transfemoral Intraluminal Graft Implantation for Abdominal Aortic Aneurysms.” Ann. Vasc. Surg., 5 (6):491-9 (1991).
Pavcnik et al., “Percutaneous Bioprosthetic Venous Valve: A Long-term Study in Sheep.” J. of Vascular Surg., 35(3): 598-603, Mar. 2002.
Pavcnik et al., “Development and Initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement.” Radiology 183:151-54 (1992).
Pavcnik, et al., “Aortic and venous valve for percutaneous insertion,” Min. Invas. Ther. & Allied Technol. 9(3/4) 287-292 (2000).
Phillips et al., “A Temporary Catheter-Tip Aortic Valve: Hemodynamic Effects on Experimental Acute Aortic Insufficiency.” Annals of Thoracic Surg., 21(2): 134-136, Feb. 1976.
Printz, et al., “Let the Blood Circulate.” Sulzer Tech. Rev. 4/99.
U.S. Appl. No. 60/553,945 to White.
Raillat et al., “Treatment of Iliac Artery Stenosis with the Wallstent Endoprosthesis.” AJR 154(3):613-6 (Mar. 1990).
Remadi et al., “Preliminary results of 130 aortic valve replacements with a new mechanical bileaflet prosthesis: the Edwards MIRA valve” Interactive Cardiovasc. and Thorac. Surg. 2, 80-83 (2003).
Rosch et al., “Gianturco-Rosch Expandable Z-Stents in the Treatment of Superior Vena Cava Syndrome.” Cardiovasc. Intervent. Radiol. 15: 319-327 (1992).
Schurink et al,. “Stent Attachment Site-related Endoleakage after Stent Graft Treatment: An in vitro study of the effects of graft size, stent type, and atherosclerotic wall changes” J. Vasc. Surg., 30(4):658-67 (Oct. 1999).
Seminars in Interventional Cardiology, ed. P.W. Surruys, vol. 5 (2000).
Sochman et al., “Percutaneous Transcatheter Aortic Disc Valve Prosthesis Implantation: A Feasibility Study.” Cardiovasc. Intervent Radiol., 23: 384-388, Sep. 2000.
Southern Lights Biomaterials Homepage, http://www.slv.co.nz/, Jan. 7, 2011.
Stanley et al., “Evaluation of Patient Selection Guidelines for Endoluminal AAA Repair With the Zenith Stent Graft: The Australasian Experience ” J. Endovasc. Ther. 8:457-464 (2001).
Thompson et al., “Endoluminal stent grafting of the thoracic aorta: Initial experience with the Gore Excluder,” Journal of Vascular Surgery, 1163-70 (Jun. 2002).
Steinhoff et al., “Tissue Engineering of Pulmonary Heart Valves on Allogenic Acellular Matrix Conduits.” Circulation, 102 [suppl. III]: III-50-III-55 (2000).
Stuart, “In Heart Valves, A Brave, New Non-Surgical World.” Start-Up. 9-17, Feb. 2004.
Supplemental Search Report from EP Patent Office, EP Application No. 04815634.3, dated Aug. 19, 2011.
Supplemental Search Report from EP Patent Office, EP Application No. 05758878.2, dated Oct. 24, 2011.
Textbook of Interventional Cardiology, 2d Ed., Chapter 75: Percutaneous Expandable Prosthetic Valves (1994).
Stassano, “Mid-term Results of the Valve on Valve Technique for Bioprosthetic failure.” European journal of Ccardiothoracic Surgery:vol 18, 453-457, Oct. 2000.
Topol, “Percutaneous Expandable Prosthetic Valves.” Textbook of Interventional Cardiology, W.B. Saunders Company, 2: 1268-1276, 1994.
Vahanian et al., “Percutaneous Approaches to Valvular Disease.” Circulation, 109: 1572-1579, Apr. 6, 2004.
Van Herwerden et al., “Percutaneous Valve Implantation: Back to the Future?” Euro. Heart J., 23(18): 1415-1416, Sep. 2002.
VentureBeatProfiles, Claudio Argento, Jan. 7, 2010, http://venturebeatprofiles.com/person/profile/claudio-argento.
Vossoughi et al.. Stent Graft Update (2000)—Kononov, Volodos, and Parodi and Palmaz Stents; Hemobahn Stent Graft.
White et al., “Endoleak as a Complication of Endoluminal Grafting of Abdominal Aortic Aneurysms: Classification, Incidence, Diagnosis, and Management.” J. Endovac. Surg., 4:152-168 (1997).
Yoshioka et al., “Self-Expanding Endovascular Graft: An Experimental Study in Dogs.” AJR 151: 673-76 (Oct. 1988).
USPTO Case IPR2017-01293, U.S. Pat. No. 8,992,608 B, Oct. 13, 2017.
Zhou et al., “Self-expandable Valved Stent of Large Size: Off-Bypass Implantation in Pulmonary Position.” Eur. J. Cardiothorac, 24: 212-216, Aug. 2003.
Gore Excluder Instructions for Use (2002).
USPTO Case IPR2016-_, U.S. Pat. No. 8,992,608 “Petition for Interpartes Review of U.S. Pat. No. 8,992,608” Oct. 12, 2016.
USPTO Case IPR 2017-0006, U.S. Pat. No. 8,992,608 B2, “Final Written Decision” dated Mar. 23, 2018.
Fluency Vascular Stent Graft Instructions for Use (2003).
International Search Report and Written Opinion dated Mar. 18, 2020 for International Application No. PCT/US2019/065454.
Related Publications (1)
Number Date Country
20200179117 A1 Jun 2020 US
Provisional Applications (1)
Number Date Country
62777487 Dec 2018 US